

BMJ Open

Bio-Plex immunoassay measuring the quantity of lysosomal N-acetylgalactosamine-6-sulfatase protein in dried blood spots for mucopolysaccharidosis IVA newborn screening purpose

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014410
Article Type:	Research
Date Submitted by the Author:	23-Sep-2016
Complete List of Authors:	Chuang, Chih-Kuang; Mackay Memorial Hospital, Departments of Medical Research; Mackay Memorial Hospital, Lin, Hsiang-Yu; Mackay Memorial Hospital, Pediatrics Wang, Tuan-Jen ; Mackay Memorial Hospital, Departments of Medical Research Huang, Sung-Fa ; Mackay Memorial Hospital, Departments of Medical Research Lin, Shuan-Pei; Mackay Memorial Hospital, Department of Pediatrics
Primary Subject Heading:	Diagnostics
Secondary Subject Heading:	Genetics and genomics
Keywords:	mucopolysaccharidosis IVA, lysosomal storage disorder, N-acetylgalactosamine-6-sulfatase, newborn screening, dried blood spot, Bio-Plex immunoassay

SCHOLARONE™
Manuscripts

Bio-Plex immunoassay measuring the quantity of lysosomal N-acetylgalactosamine-6-sulfatase protein in dried blood spots for mucopolysaccharidosis IVA newborn screening purpose

Chih-Kuang Chuang^{1,4,5*†}, Hsiang-Yu Lin^{†1,2,6,7}, Tuan-Jen Wang³, Sung-Fa Huang³, and Shuan-Pei Lin^{1,2,7,8}

Affiliations: ¹Division of Genetics and Metabolism, Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan; ²Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan; ³Department of Laboratory Medicine, Mackay Memorial Hospital, Taipei, Taiwan; ⁴Institute of Biotechnology, National Taipei University of Technology, Taipei, Taiwan; ⁵College of Medicine, Fu-Jen Catholic University, Taipei, Taiwan; ⁶Department of Early Childhood Care and Education, Mackay Junior College of Medicine, Nursing and Management, Taipei, Taiwan; ⁷Department of Medicine, Mackay Medical College, Taipei, Taiwan; ⁸Department of Infant and Child Care, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.

[†]Equal contributors

Disclosure/Conflict of Interest: The authors have no conflicts of interest relevant to this article to disclose.

Funding Source: This study was supported by research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-104-2314-B-195-019, and MOST-102-2314-B-195-006) and Mackay Memorial Hospital (MMH-103-13 and MMH-103-115).

Financial Disclosure: The authors have no financial relationships relevant to this article to disclose.

***Address correspondence to:** Chih-Kuang Chuang, Ph.D. Department of Medical Research, MacKay Memorial Hospital, No. 45, Minsheng Rd., Tamshui District, New Taipei City 25160, Taiwan. [mmhcck@gmail.com], 886-2-28094661 ext. 2348.

Abbreviations

MPS, mucopolysaccharidosis;

GALNS, N-acetylgalactosamine-6-sulfatase;

LSDs, lysosomal storage disorders;

GAGs, glycosaminoglycans;

ERT, enzyme replacement therapy;

4MU, 4-methyumbelliferone;

DBS, dried blood spot;

ELISA, enzyme-linked immunosorbent assay;

CV%, Coefficient of Variance;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective: Mucopolysaccharidosis (MPS) IVA is an autosomal recessive lysosomal storage disorder caused by the deficiency of N-acetylgalactosamine-6-sulfatase (GALNS) resulting in excessive lysosomal storage of keratan sulfate. Treatments for MPS IVA have recently become available with optimal outcomes associated with early diagnosis and treatment which can be achieved by newborn screening.

Design: Newborn screening program for mucopolysaccharidosis IVA (MPS IVA) pilot study.

Setting: Taipei MacKay Memorial Hospital (MMH), and another 3 branch hospitals in Taiwan.

Participants: A total of 7,415 infants was born in 4 branch hospitals of MMH and had joined the MPS IVA newborn screening programme. Written informed consents were obtained from parents prior to the screening process (12MMHIS188 approved by MacKay Memorial Hospital Institutional Review Board).

Outcome measures: An alternative newborn screening method for MPS IVA has been performed. Screening involved measuring the quantity of GALNS in dried blood spot (DBS) from newborn infants using the Bio-Plex immunoassay. The amount of fluorescence sorting detected by YAG laser was proportional to the quantity of GALNS protein.

Results: Of the 7,415 neonates analyzed, eight infants whose GALNS levels were below the cut-off value of 8.49 $\mu\text{g/L}$ had been recalled for a second DBS collection. The reference values were 8.30-27.43 $\mu\text{g/L}$. In confirmed MPS IVA patients (n=11), the GALNS activities were far below 5% of the normal population.

Conclusion: The Bio-Plex immunoassay is a validated method used for measuring GALNS protein in DBS and has the potential to be adopted for MPS IVA newborn screening purpose.

Trial registration number: 12MMHIS188 approved by MacKay Memorial Hospital Institutional Review Board.

Key words: mucopolysaccharidosis IVA, lysosomal storage disorder, N-acetylgalactosamine-6-sulfatase, newborn screening, dried blood spot, Bio-Plex immunoassay.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- The Bio-Plex immunoassay is a well-established, feasible method used for measuring GALNS protein in DBS and has the potential to be adopted for MPS IVA newborn screening purpose.
- The early diagnosis of MPS IVA in infantile period is valuable, preventable, and treatable.
- No any positive case has been found that is the limitation in this study.

For peer review only

INTRODUCTION

Mucopolysaccharidoses (MPSs), a group of rare genetic diseases known as lysosomal storage disorders (LSDs), are caused by the deficiency of enzymes that catalyze the stepwise degradation of glycosaminoglycans (GAGs). Mucopolysaccharidosis IVA (MPS IVA, Morquio syndrome; OMIM#253000) is a disease characterized by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase (GALNS; EC 3.1.6.4). This deficiency leads to excessive lysosomal storage of keratan sulphate and chondroitin-6-sulfate resulting in devastating manifestations, such as systemic skeletal dysplasia, short stature, joint abnormalities that limit mobility and endurance, malformation of the thorax, which impairs respiratory function, odontoid hypoplasia and ligamentous laxity which causes cervical spinal instability and potentially cord compression. Other symptoms of MPS IVA include hearing loss, corneal clouding and valvular heart disease.¹⁻⁴ Initial symptoms often present during the first 5 years of life depending on disease severity or age of diagnosis.

Few studies have investigated the incidence (or prevalence) of MPS. The overall incidence of MPS was estimated to be 1 in 10,000–25,000 births in Europe.^{1, 5-6} The highest incidence of MPS IVA was reported in Northern Ireland with a rate of 1.31 in 100,000 live births,⁷ which was substantially higher compared with other countries such as Germany, Poland and Tunisia. The birth incidences of MPS IVA in those countries were estimated to be between 0.14 and 0.45 cases in 100,000 live births.⁸⁻¹⁰ In Taiwan, the birth incidence for all MPS cases was 2.04 per 100,000 live births investigated from

January 1984 to December 2004,¹¹ with MPS IV incidence estimated at 0.33 per 100,000 live births, accounting for 16% of all MPS cases in Taiwan.

Recently, treatments have become available for some of MPS subtypes and these include haematopoietic stem cell transplantation,^{12,13} enzyme replacement therapy (ERT),^{12,14-17} premature stop codon read-through^{18,19} and vector-mediated gene therapy.²⁰⁻²² ERTs are available for MPS I, MPS II, MPS IVA and MPS VI. ERT with recombinant human GALNS (elosulfase alfa) was approved in 2014 and is the first systemic treatment available for patients with MPS IVA.

Optimal benefits from ERT, particularly for MPS IVA patients who suffer from devastating cartilage disease, would require commencement of treatment before the onset of irreversible clinical disease. With the exception of cases where there is a family history of the disease, pre-symptomatic detection of MPS can only be achieved by newborn screening. Recent progress towards newborn screening for LSDs holds promise for early detection.²³⁻²⁵

MPS is diagnosed by a decrease in or loss of enzyme activity, usually involving a fluorescent-tagged artificial substrate such as 4-methyumbelliferone (4MU) or a natural substrate in which a fragment of biological substrate is labelled with a radio-stable isotope. Homogenates of cultured fibroblasts and leukocytes have been widely used for definitive diagnoses of LSDs. The use of dried blood spot (DBS) samples offer several

advantages in terms of cost, transportation and suitability of sample collection from neonates.

We previously reported findings from a pilot study of newborn screening for MPS I in Taiwan using the 4MU fluorescent enzymatic assay and have analyzed more than 67,500 samples since 2008²³. The 4MU enzymatic assay for GALNS enzyme activity in DBS has not been proven to be consistently successful since 2010.²⁶⁻²⁸ Even though the recent study showed that GALNS can be reliably and accurately measured by mass spectrometry in DBS,²⁶ the quality and the stability of the synthesized substrate, as well as the commercialization are all needed to be clarified further. In this study, we reported to conduct a pilot study to determine the utility of the Bio-Plex immunoassay for the quantitation of GALNS protein in DBS as an alternative method used for MPS IVA newborn first-line biochemistry examination in Taiwan. The Bio-Plex immunoassay has many advantages, such as high specificity, high throughput, quantitative assay, and easy-to-use 96-well plate-based suspension analysis system. Similar to enzyme-linked immunosorbent assay (ELISA) (Figure 1), the Bio-Plex assay utilizes antibody-coupled magnetic beads (capture beads) to react and bind first with the antigen (GALNS protein) eluted from the DBS sample. The antigen-antibody complex is then treated by biotinylated detection antibodies and a reporter streptavidin-phycoerythrin conjugate. Fluorescence intensity of the reporter conjugate is then measured to determine GALNS quantities. The reading intensity of the fluorescence is proportional to the amount of GALNS protein in the DBS sample.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PARTICIPANTS AND METHODS

Preparation of DBS samples

DBS samples were obtained according to the National Committee for Clinical Laboratory Standards protocol (NCCLS standard LA4-A4), “Blood Collection on Filter Paper for Neonatal Screening Program”.^{29, 30} Blood samples were collected by heel puncture on the second day of life. Drops of blood were spotted directly on filter paper (ToYo PKU No. 545, Japan) and dried at room temperature for at least 4 hours. DBS samples were stored at 4°C in zipper-lock plastic bags prior to quantitative analysis of GALNS protein by Bio-Plex immunoassay.

Between December 2013 and November 2015, a total of 7,415 DBS samples were collected from neonates born in the main medical centre and three other branches of MacKay Memorial Hospital in Taiwan. Written informed consents were obtained from the parents prior to the screening process (12MMHIS188 approved by MacKay Memorial Hospital Institutional Review Board). The infant examinees were defined as normal GALNS levels in DBS about 95% of the values lie within two standard deviations. The reference values of GALNS levels in normal infants (n=365) were calculated by using Microsoft Excel 2013, and the Shapiro-Wilk Test of normality was also determined. Eleven DBS samples from confirmed MPS IVA patients were used as positive controls for every batch of test. The averaged ages of the 11 MPS IVA patients were 15.6 years old (\pm 5.5), and all the patients were with significant clinical manifestation, particularly

systemic skeletal dysplasia including bone deformities like gibbus, genu valgum and dysostosis multiplex, and all the patients had no symptom of central nervous system involvement.

Assay validation tests

In the study, ten DBS samples obtained from normal volunteers were run and calculated for within-run and between-run precisions (Coefficient of Variance; CV %). All the 10 samples were run in 6 consecutive replicates for within-run analysis, and a duplicate analysis of each sample (n = 10) was performed on 6 different days sequentially. In addition, EDTA blood samples were collected from normal volunteers (n=20) and pooled, which were used to make a normal control (C1, n = 20) and an inactivated control (C2, n = 20), in which the inactivated control DBS samples were placed in a 50°C oven for 96 hours to degrade GALNS. These control DBS samples were used for assay quality control.

In this study, control DBS samples were collected and stored in low gas-permeability plastic bags at -30°C until analysis. The precision of the assay was performed to assess the repeatability. In order to ensure the stability and the accuracy of Bio-Plex immunoassay in DBFPs, the within-run and between-run precisions of DBS controls (C1 and C2) were evaluated. All prepared DBFP samples were run in six consecutive replicates for the within-run analysis, while a duplicate analysis of each sample was performed on six different days sequentially for the between-run precision. Recovery analysis was also performed by spiking aqueous GALNS working standard (25.0

µg/L) into EDTA whole blood obtained from the same volunteers with appropriate ratio in volumes.

Bio-Plex immunoassay workflow

The MPS IVA specific Bio-Plex immunoassay was performed using the Bio-Plex® 200 System (Bio-Rad Laboratories, Hercules, CA, USA) as described.^{31, 32} DBSs (3.175 mm diameter) were punched from the DBS samples for GALNS protein elution. Each DBS was transferred to one well in a 96-well plate and eluted overnight (16 hours) at 4°C in 130 µL phosphate-saline buffer (0.05% Tween, 20.05% bovine serum albumin, 0.05% γ-globulin and 0.05% sodium azide; pH 7.4). A Bio-Plex Pro™ Magnetic COOH bead (bead #35; Luminex Corp., Austin, TX, USA) was used in this study. The protein coupling was performed according to the instruction manual issued by Bio-Rad Laboratories. The coupling procedure comprises a two-step carbodiimide reaction. The carboxyl groups on the bead surface were first activated to form an active O-acylisourea intermediate by employing EDAC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride). Then, the intermediate was further formed a more stable ester by treating with S-NHS (N-hydroxysulfosuccinimide), and the stable ester was ready for proceeding the protein coupling reaction. In this study, approximate 6.25×10⁶ carboxylated beads (500µL) were required and prepared for the coupling reaction. The protein coupling reaction was performed by adding 50µL (1 mg/mL) primary GALNS antibody (rabbit polyclonal antibody SAB 1410481, purchased from Sigma-Aldrich Co., St Louis, MO, USA.) to 450µL

well-activated bead suspension by gentle agitation on shaker in dark for 2 hours at room temperature.

DBS eluates (50 μ L) were then incubated with capture beads (2500 beads/analyte/well), and each with unique spectral address coated with the primary GALNS antibody for 16 hours at 4°C. Subsequently, biotin-labelled reporter antibody (133 μ g/L in concentration; mouse monoclonal antibody ab 69957; Abcam, Cambridge, UK) were added to the wells and incubated for an additional 2 hours. Free primary antibodies were washed out by filtration using a magnetic plate carrier to recover the magnetic beads irrespective of primary antibody coating. The beads were then incubated in streptavidin–phycoerythrin solution (PE; 1.2 mg/L, 50 μ L/well) at room temperature for 30 minutes. After gentle removal of the supernatant from the wells, the beads were resuspended in phosphate-saline buffer (125 μ L/well). Specificity of antibodies to GALNS protein was verified by using dot-blot assay, and the results showed that the specificities of Ag-Ab reactions were good and satisfactory (Figure 2).

Fluorescence intensity of the beads was determined using the Bio-Plex Protein Array System with the Bio-Plex Manager 3.1 software (Bio-Rad, Hercules, CA, USA). The amounts of fluorescence sorting detected by YAG laser with wavelengths of 532 (exciting) and 580 nm (emission) was proportional to the quantity of GALNS protein (expressed as μ g/L).

Calibration curve

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Fresh-made working calibrators were prepared by serial dilutions of GALNS stock solution (1 mg/mL). The human recombinant GALNS protein was purchased from R&D Systems, Inc. (Minneapolis, MN, USA), and the final concentrations of working standards were 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, and 0.39 µg/L. Biotin was used as a blank. The GALNS calibration curve (fluorescence intensity against the logarithm of concentrations) was made and showed linear between the concentrations of 0.39 and 12.5 µg/L of GALNS working standards, whereas it illustrated non-linear above the concentrations of 25 µg/L according to the Logistic 5-PL model. The regression analysis (r^2) of the calibration curve (fluorescence reading versus concentrations of GALNS calibrations) was excellent ($r^2 = 0.991$). The correlation of observed versus expected results was 0.999855.

RESULTS

Precision of Bio-Plex immunoassay for GALNS quantitation

A total of ten samples were run and calculated for within-run and between-run precisions (coefficient of variance %; CV%). The within-run and between-run precisions of DBS Bio-Plex immunoassay were 10.74% and 9.37%, respectively. In order to ensure the stability and the accuracy of Bio-Plex immunoassay in DBS, the within-run and between-run precisions of control DBSs (C1 and C2) were also evaluated. The within-run and between-run of C1 and C2 were 7.74% and 9.07%, as well as 6.82% and 12.42%, respectively. The averaged quantities of GALNS were 14.09 (± 3.43) $\mu\text{g/L}$ for C1 and 6.58 (± 1.15) $\mu\text{g/L}$ for C2. The recovery of GALNS using Bio-Plex Immunoassay was excellent, about 94.3%.

Quantification of GALNS in DBSs

Of the 7,415 samples analyzed, 132 (1.78%) samples had GALNS levels below the cut-off value of 13.19 $\mu\text{g/L}$ at the first time test. Most of these (n=124) were excluded and results showed normal when the original DBS samples were reanalyzed. Only eight had been recalled for a second DBS collection and repeated the analysis (recall rate = 0.108%). In those, the GALNS quantities were all greater than 8.49 $\mu\text{g/L}$ (the cut-off value of the 2nd time test). No any positive case has been reported so far in this study.

The reference values of GALNS levels in DBS samples using Bio-Plex immunoassay were 8.30-27.43 $\mu\text{g/L}$, with a mean of 17.86 (± 4.78) (Figure 3). Sampling to determine

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

the reference values of GALNS in newborn controls showed a 5,000 samples, Shapiro-Wilk Test, $p=0.538$ (Figure 4). In confirmed MPS IVA patients who did not receive ERT ($n=11$), the GALNS quantities were almost near to the lower limit of detection (< 0.39 $\mu\text{g/L}$) that were far below those of 5% of unaffected control. The GALNS quantities in carrier parents identified from two confirmed MPS IVA patients ($n=3$) were between 12.34 and 16.53 $\mu\text{g/L}$ (14.17 ± 1.52), which were all situated within the normal reference values.

Proposed algorithm for newborn screening for MPS IVA

Based on our findings, we propose a diagnostic algorithm for newborn first-line screening for MPS IVA as described in Figure 5. Two levels of testing of the original DBS sample were proposed to rule out the false positive results, particularly in carriers. The cut-off values of the 1st time test and the 2nd time of testing were determined according to the mean and SD. In order to reduce the numbers of false-positive cases, the cut-off values of the 1st test and the 2nd time of testing were set at minus 1SD and 2SD from the mean value, respectively. The cut-off point of GALNS quantity in DBS using Bio-Plex immunoassay was 13.19 $\mu\text{g/L}$ for the first time and 8.49 $\mu\text{g/L}$ for the second time test of testing. Infants who had GALNS level below the cut-off point of 8.49 $\mu\text{g/L}$ were likely to be the highly suspicious cases and should be recalled for a second DBS sample collection. Confirmative diagnoses including leukocyte enzymatic assay and molecular DNA analysis

1
2
3 should be performed further regarding the significant reduction of GALNS level being
4
5
6 detected by the second time of testing.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

DISCUSSION

Currently, there is no general consensus for the method used for MPS IVA newborn screening. Multiplex assays for quantitative measurement of GALNS activity using tandem mass spectrometry have been developed and reported since 2010;²⁶⁻²⁸ however, the 4MU enzymatic assay has not been applied widely due to the stability of the synthesized substrate. Besides, GALNS activity and/or GAG biomarkers, particularly the keratan sulfate in blood, urine, or even DBS, can be detected quantitatively using tandem mass spectrometry method, and have shown to be applicable for MPS IVA newborn screening and the prognostic assessment following ERT.³³⁻³⁵ However, the validation of clinical application, particularly for MPS IVA newborn screening purpose, is still uncertain and controversial. In this study, an alternative method, the Bio-Plex immunoassay measuring GALNS protein in DBS, is proposed and it can be an another choice to be adopted for MPS IVA first-line screening test, in which it can provide relatively feasible and reliable result for early diagnosis of MPS IVA. Several similar immunoassays like immune-quantification assay, immune-capture method and time-resolved fluorometry with the DELFIA method had been developed to screen populations for lysosomal storage disorders (LSD), including MPS.³⁶⁻³⁹ However, the applications and validations of LSD diagnosis are different. The principle of immune-quantification assay is similar with the method we presented in this study, which can accurately quantify lysosomal proteins in DBS.³⁷ There were many issues raised by using immunoassay for LSD screening and diagnostic purpose, for instance, the stability of

protein level in DBS? Protein level changing through the life? And protein level correlated with clinical severity?

According to literatures reported, the LSD enzyme activities in DBS may decrease during transportation and storage but protein determinations will be no change as has been reported for arylsulfatase A by Tan, et al.³⁷ In order to verify any difference in the amount of GALNS protein by age, we have collected both plasma and DBS samples from 34 unaffected control in variety of ages, in which 3 age groups were divided including group 1 (< 2 years old; n=9), group 2 (2-17 years old; n=12), and group 3 (over 18 years old; n=13). All the samples were performed measuring GALNS protein based on the same method described above. From the results both found in plasma and DBS samples we obtained, there were no significant differences between group1 and group 2, as well as between group 2 and group 3, whereas the results showed small bio-statistic differences ($p<0.05$) between group 1 and group 3 (data not shown). The conclusion is the amount of GALNS protein is changing through the life, but not very noticeable, and the changing of protein level in different age groups will not influence the judgment of attenuated phenotype by using Bio-Plex immunoassay for measuring GALNS protein under this circumstance. Whether or not the protein level correlates with clinical severity? The prediction of clinical severity with a single marker is somewhat limited. Combined markers including immune-detectable protein and enzyme activity are partially predictive of clinical severity.^{38, 39}

The Bio-Plex immunoassay for measuring GALNS protein in DBS reported in this study is relatively simple when compared with the other methods described above. The calculated recall rate of GALNS immunoassay had been examined, approximately less than 0.108%. The results suggest that the Bio-Plex immunoassay is practicable for MPS IVA newborn first-line screening purpose due to the rational percentage of false-positive cases. The only concerned query we raised for Bio-Plex immunoassay is the false-negative results that may be happened due to the production of enzymatic non-functional protein. According to literature reported,⁴⁰ most GALNS mutations identified were point mutations, particularly the missense mutation, and small deletions. Transient expression analysis of some mutations showed deficiency or low residual GALNS activity due to nonsense codon in the transcribed mRNA and thus the protein to be incorrectly translated. Results also revealed that the configuration of GALNS protein might be distinctly changed because of the destruction of hydrophobic core, salt bridge removal, and modification of active site.⁴⁰⁻⁴² Based on the above evidences, false negative results would be happened, but should be very rare.

CONCLUSION

To date, very few methods for MPS IVA newborn screening have been reported and none have been clinically adopted. The Bio-Plex immunoassay proposed in this pilot study is a reliable, specific, validated, simple and cost-effective method for measuring GALNS protein in DBS and has the potential to be adopted for MPS IVA newborn screening purpose. More collaborating with other newborn screening centres in Taiwan are required to confirm the validation of the method that provides appropriate methodology to screen out more suspicious patients to enable early diagnosis and treatment before the onset of irreversible symptoms.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENTS

All authors have disclosed potential conflicts of interest and all authors have read the journal's policy on conflicts of interest and the journal's authorship agreement. The authors express their sincere thanks to the staff of the Department of Clinical Laboratory and the Department of Pediatrics at MacKay Memorial Hospital for the collection of samples. This study was supported by the research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-104-2314-B-195-019, and MOST-102-2314-B-195-006) and Mackay Memorial Hospital (MMH 105-55, MMH-I-S-600 and MMH-10352). The writing assistance was provided by Stefanie Chuah, from Mudskipper Shanghai Ltd, funded by BioMarin.

AUTHORS' CONTRIBUTIONS:

Dr. Chih-Kuang Chuang and Dr. Hsiang-Yu Lin are equal contributors, and participated in this pilot study design, immunoassay development by using dried blood spot filter paper, statistical analysis, data interpretation, and drafting of the manuscript. Dr. Shuan-Pei Lin performed acquisition and interpretation of the data, as well as helped to revise the manuscript. Mr. Tuan-Jen Wang and Sung-Fa Huang coordinated and supervised data collection at Taipei MacKay Memorial Hospital and another three branch hospitals in Taiwan, and performed Bio-Plex immunoassay and data collection. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Funding Source: This study was supported by research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-104-2314-B-195-019, and MOST-102-2314-B-195-006) and Mackay Memorial Hospital (MMH-103-13 and MMH-103-115).

Financial Disclosure: The authors have no financial relationships relevant to this article to disclose.

Competing interests: None declared.

Patient consent: Written informed consents obtained.

Ethics approval MacKay Memorial Hospital (12MMHIS188).

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: No additional data are available.

Open Access: This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

For peer review only

REFERENCES

1. Neufeld E and Muenzer J 2001. The mucopolysaccharidoses. In C. Scriver, A. Beaudet, W. Sly, and D. Valle, editors The metabolic and molecular bases of inherited disease, 8th ed. McGraw-Hill, New York, USA. 3421-3452.
2. Montano AM, Tomatsu S, Gottesman GS, et al. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007; 30(2):165-174.
3. Wood TC, Harvey K, Beck M, et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013; 36(2):293-307.
4. Lin HY, Chuang CK, Chen MR, et al. Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. Orphanet J Rare Dis. 2014; 9:21.
5. Besley GTN and Wraith JE. Lysosomal disorders. Current Paediatrics. 1997; 7(2):128-134.
6. Wraith JE. Mucopolysaccharidoses. Current Paediatrics. 1996; 6(2):74-79.
7. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997; 101(3):355-358.

8. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. *J Inherit Metab Dis*. 2005; 28(6):1011-1017.

9. Jurecka A, Lugowska A, Golda A, et al. Prevalence rates of mucopolysaccharidoses in Poland. *J Appl Genet*. 2015; 56(2):205–210.

10. Ben TH, Tebib N, Azzouz H, et al. Incidence of mucopolysaccharidoses in Tunisia. *Tunis Med*. 2009; 87(11):782–785.

11. Lin HY, Lin SP, Chuang CK, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. *Am J Med Genet A*. 2009; 149A (5):960–964.

12. Patel P, Suzuki Y, Tanaka A, et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter Syndrome. *Mol Genet Metab Rep*. 2014; 1:184–196.

13. Tanjuakio J, Suzuki Y, Patel P, et al. Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation. *Mol Genet Metab*. 2015; 114(2):161–169.

14. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). *J Pediatr*. 2004; 144(5):581–588.

- 1
2
3 15. Tomatsu S, Alméciga-Díaz C, Barbosa H, et al. Therapies of mucopolysaccharidosis
4
5 IVA (Morquio A syndrome). *Expert Opin Orphan Drugs*. 2013; 1(10):805–818.
6
7
8
- 9
10 16. Decker C, Yu ZF, Giugliani R, et al. Enzyme replacement therapy for
11
12 mucopolysaccharidosis VI: Growth and pubertal development in patients treated
13
14 with recombinant human N-acetylgalactosamine 4-sulfatase. *J Pediatr Rehabil Med*.
15
16 2010; 3(2):89–100.
17
18
- 19
20 17. Tomatsu S, Montano AM, Oikawa H, et al. Enzyme replacement therapy in newborn
21
22 mucopolysaccharidosis IVA mice: early treatment rescues bone lesions? *Mol Genet*
23
24 *Metab*. 2015; 114(2):195–202.
25
26
27
- 28
29 18. Brooks DA, Muller VJ, Hopwood JJ. Stop-codon read-through for patients affected
30
31 by a lysosomal storage disorder. *Trends Mol Med*. 2006; 12(8):367–373.
32
33
34
- 35
36 19. Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA. alpha-L-
37
38 iduronidase premature stop codons and potential read-through in
39
40 mucopolysaccharidosis type I patients. *J Mol Biol*. 2004; 338(3):453–462.
41
42
43
- 44
45 20. Sands MS and Haskins ME. CNS-directed gene therapy for lysosomal storage
46
47 diseases. *Acta Paediatr Suppl*. 2008; 97(457):22–27.
48
49
- 50
51 21. Di Domenico C, Villani G, Di Napoli D, et al. Intracranial gene delivery of LV-NAGLU
52
53 vector corrects neuropathology in murine MPS IIIB. *Am J Med Genet A*. 2009; 149A
54
55

(6):1209–1218.

22. Cearley CN and Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. *J Neurosci.* 2007; 27(37):9928–9940.

23. Lin SP, Lin HY, Wang TJ, et al. A pilot newborn screening program for mucopolysaccharidosis type I in Taiwan. *Orphanet J Rare Dis.* 2013; 8: 147.

24. Scott CR, Elliott S, Buroker N, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. *J Pediatr.* 2013; 163(2):498–503.

25. Ruijter GJ, Goudriaan DA, Boer AM, et al. Newborn screening for hunter disease: a small-scale feasibility study. *JIMD Rep.* 2014; 14: 23–27.

26. Kumar AB, Masi S, Ghomashchi F, et al. Tandem Mass Spectrometry Has a Larger Analytical Range than Fluorescence Assays of Lysosomal Enzymes: Application to Newborn Screening and Diagnosis of Mucopolysaccharidoses Types II, IVA, and VI. *Clin Chem.* 2015; 61: 1363-71.

27. Duffey TA, Khaliq T, Scott CR, et al. Design and synthesis of substrates for newborn screening of Maroteaux-Lamy and Morquio A syndromes. *Bioorg Med Chem Lett.* 2010; 20: 5994–5996.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. Khaliq T, Sadilek M, Scott CR, et al. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis IVA. *Clin Chem*. 2011; 57: 128–131.
29. National Committee for Clinical Laboratory Standards (NCCLS). Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard-Fourth Edition, NCCLS document LA4-A4. 2003. 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, National Committee for Laboratory Standards.
30. De Jesus V, Zhang XK, Keutzer J, et al. Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. *Clin Chem*. 2009; 55(1):158–164.
31. Meikle PJ, Grasby DJ, Dean CJ, et al. Newborn screening for lysosomal storage disorders. *Mol Genet Metab*. 2006; 88(4):307–314.
32. Parkinson-Lawrence EJ, Muller VJ, Hopwood JJ, et al. N-acetylgalactosamine-6-sulfatase protein detection in MPS IVA patient and unaffected control samples. *Clin Chim Acta*. 2007; 377(1-2):88–91.
33. Tomatsu S, Fujii T, Fukushi M, et al. Newborn screening and diagnosis of mucopolysaccharidoses. *Mol Genet Metab*. 2013; 110(1-2):42–53.
34. Tomatsu S, Kubaski F, Sawamoto K, et al. Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry. *Nihon Masu*

Sukuriningu Gakkai Shi. 2014; 24: 19–37.

35. Tomatsu S, Shimada T, Mason RW, et al T. Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. J Anal Bioanal Tech. 2014 Mar 1; 2014(Suppl 2): 006

36. Tan MA, Dean CJ, Hopwood JJ, et al. Diagnosis of metachromatic leukodystrophy by immune quantification of arylsulphatase A protein and activity in dried blood spots. Clin Chem. 2008; 54(11):1925-7.

37. Fuller M, Tucker JN, Lang DL, et al. Screening patients referred to a metabolic clinic for lysosomal storage disorders. J Med Genet. 2011; 48(6):422-5.

38. Parkinson-Lawrence E, Fuller M, Hopwood JJ, et al. Immunochemistry of lysosomal storage disorders. Clin Chem. 2006; 52(9):1660-8.

39. Fuller M, Brooks DA, Evangelista M, et al. Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab. 2005; 84(1):18-24.

40. Sukegawa K, Nakamura H, Kato Z, et al. Biochemical and structural analysis of missense mutations in N-acetylgalactosamine-6-sulfate sulfatase causing mucopolysaccharidosis IVA phenotypes. Hum Mol Genet. 2000; 9: 1283-90.

41. Bond CS, Clements PR, Ashby SJ, et al. Structure of a human lysosomal sulfatase. Structure. 1997; 5: 277-89.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
42. Lukatela G, Krauss N, Theis K, et al. Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. *Biochemistry*. 1998; 37: 3654-64.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Schematic representation of the Bio-Plex immunoassay. The anti-GALNS antibody-coated magnetic beads (capture beads) reacts and binds with GALNS protein from the DBS sample then reacts with biotininated detection antibodies.


Figure 2. The specificities of primary and secondary antibodies to antigen (GALNS) have been assured by employing dot-blotting assay. Ab.1 stands for anti-IDS antibody (Abcam 113908, 20 ng) ; Ab. 2 for anti-GALNS antibody (SAB 1410481, 20 ng); Ab. 3 for anti-ARSB antibody (BPA 037770, 20 ng).

Figure 3. The GALNS concentrations (ranges) in dried blood spots from normal control ($17.86 \pm 4.78 \mu\text{g/L}$, $n=468$), carriers ($14.17 \pm 1.52 \mu\text{g/L}$, $n=3$) and confirmed MPS IVA patients ($0.88 \pm 0.19 \mu\text{g/L}$, $n=11$).

Figure 4. Sampling to determine the reference values of GALNS in newborn controls showed normal distribution (5,000 samples, Shapiro-Wilk Test, $p=0.354$).

Figure 5. A diagnostic algorithm for MPS IVA newborn screening test.

Figure 1.



Bio-Plex Assay

Figure 2.





Figure 3.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4.





Figure 5.

MPS IVA Newborn Screening

BMJ Open

Bio-Plex immunoassay measuring the quantity of lysosomal N-acetylgalactosamine-6-sulfatase protein in dried blood spots for mucopolysaccharidosis IVA newborn screening study design

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014410.R1
Article Type:	Research
Date Submitted by the Author:	17-Mar-2017
Complete List of Authors:	Chuang, Chih-Kuang; Mackay Memorial Hospital, Departments of Medical Research; Mackay Memorial Hospital, Lin, Hsiang-Yu; Mackay Memorial Hospital, Pediatrics Wang, Tuan-Jen ; Mackay Memorial Hospital, Departments of Medical Research Huang, Sung-Fa ; Mackay Memorial Hospital, Departments of Medical Research Lin, Shuan-Pei; Mackay Memorial Hospital, Department of Pediatrics
Primary Subject Heading:	Genetics and genomics
Secondary Subject Heading:	Genetics and genomics, Diagnostics, Paediatrics
Keywords:	mucopolysaccharidosis IVA, lysosomal storage disorder, N-acetylgalactosamine-6-sulfatase, newborn screening, dried blood spot, Bio-Plex immunoassay

SCHOLARONE™
Manuscripts

Bio-Plex immunoassay measuring the quantity of lysosomal N-acetylgalactosamine-6-sulfatase protein in dried blood spots for mucopolysaccharidosis IVA newborn screening study design

Chih-Kuang Chuang^{+1,4,5*}, Hsiang-Yu Lin^{+1,2,6,7}, Tuan-Jen Wang³, Sung-Fa Huang³, and Shuan-Pei Lin^{1,2,7,8}

Affiliations: ¹Division of Genetics and Metabolism, Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan; ²Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan; ³Department of Laboratory Medicine, Mackay Memorial Hospital, Taipei, Taiwan; ⁴Institute of Biotechnology, National Taipei University of Technology, Taipei, Taiwan; ⁵College of Medicine, Fu-Jen Catholic University, Taipei, Taiwan; ⁶Mackay Junior College of Medicine, Nursing and Management, Taipei, Taiwan; ⁷Department of Medicine, Mackay Medical College, New Taipei City, Taiwan; ⁸Department of Infant and Child Care, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.

[†]Equal contributors

Disclosure/Conflict of Interest: The authors have no conflicts of interest relevant to this article to disclose.

Funding Source: This study was supported by research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-102-2314-B-195-006, MOST-104-2314-B-195-019, MOST-105-2628-B-195-001-MY3, and MOST-105-2314-B-195-013) and Mackay Memorial Hospital (MMH-103-13 and MMH-103-115).

Financial Disclosure: The authors have no financial relationships relevant to this article to disclose.

***Address correspondence to:** Chih-Kuang Chuang, Ph.D. Department of Medical Research, MacKay Memorial Hospital, No. 45, Minsheng Rd., Tamshui District, New Taipei City 25160, Taiwan. [mmhcck@gmail.com], 886-2-28094661 ext. 2348.

Abbreviations

MPS, mucopolysaccharidosis;

GALNS, N-acetylgalactosamine-6-sulfatase;

LSDs, lysosomal storage disorders;

GAGs, glycosaminoglycans;

ERT, enzyme replacement therapy;

4MU, 4-Methylumbelliferone;

DBS, dried blood spot;

ELISA, enzyme-linked immunosorbent assay;

CV%, Coefficient of Variance;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective: Mucopolysaccharidosis (MPS) IVA (Morquio syndrome A) is an autosomal recessive lysosomal storage disorder caused by the deficiency of N-acetylgalactosamine-6-sulfatase (GALNS) resulting in excessive lysosomal storage of keratan sulfate. Treatments for MPS IVA have recently become available with optimal outcomes associated with early diagnosis and treatment which can be achieved by newborn screening.

Design: Newborn screening program for MPS IVA pilot study.

Setting: Taipei MacKay Memorial Hospital (MMH), and another 3 branch hospitals in Taiwan.

Participants: A total of 7,415 newborns were born in 4 branch hospitals of MMH and had joined the MPS IVA newborn screening programme. Written informed consents were obtained from parents prior to the screening process (12MMHIS188 approved by MacKay Memorial Hospital Institutional Review Board).

Outcome measures: An alternative newborn screening method for MPS IVA has been performed. Screening involved measuring the quantity of GALNS in dried blood spot (DBS) from newborn infants using the Bio-Plex immunoassay. The amount of fluorescence sorting detected by YAG laser was proportional to the quantity of GALNS protein.

Results: Of the 7,415 neonates analyzed, eight infants whose GALNS levels were below the cut-off value of 8.30 µg/L had been recalled for a second DBS collection. The reference values were 8.30-27.43 µg/L. In confirmed MPS IVA patients (n=11), the GALNS quantities were far below 5% of the normal population.

Conclusion: The Bio-Plex immunoassay is a validated method used for measuring GALNS protein in DBS and has the potential to be adopted for MPS IVA newborn screening study design.

Trial registration number: 12MMHIS188 approved by MacKay Memorial Hospital Institutional Review Board.

Key words: mucopolysaccharidosis IVA, lysosomal storage disorder, N-acetylgalactosamine-6-sulfatase, newborn screening, dried blood spot, Bio-Plex immunoassay.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- The Bio-Plex immunoassay is a well-established, feasible method used for measuring GALNS protein in DBS and has the potential to be adopted for MPS IVA newborn screening study design.
- The early diagnosis of MPS IVA in infantile period is valuable, preventable, and treatable.
- No positive case has been found is the limitation of this study.

INTRODUCTION

Mucopolysaccharidoses (MPSs), a group of rare genetic diseases known as lysosomal storage disorders (LSDs), are caused by the deficiency of enzymes that catalyze the stepwise degradation of glycosaminoglycans (GAGs). Mucopolysaccharidosis IVA (MPS IVA, Morquio syndrome A; OMIM#253000) is a disease characterized by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase (GALNS; EC 3.1.6.4). This deficiency leads to excessive lysosomal storage of keratan sulphate and chondroitin-6-sulfate resulting in devastating manifestations, such as systemic skeletal dysplasia, short stature, joint abnormalities that limit mobility and endurance, malformation of the thorax, which impairs respiratory function, odontoid hypoplasia and ligamentous laxity which causes cervical spinal instability and potentially cord compression. Other symptoms of MPS IVA include hearing loss, corneal clouding and valvular heart disease.¹⁻⁴ Initial symptoms often present during the first 5 years of life depending on disease severity or age of diagnosis.

Few studies have investigated the incidence (or prevalence) of MPS. The overall incidence of MPS was estimated to be 1 in 10,000–25,000 births in Europe.^{1, 5-6} The highest incidence of MPS IVA was reported in Northern Ireland with a rate of 1.31 in 100,000 live births,⁷ which was substantially higher compared with other countries such as Germany, Poland and Tunisia. The birth incidences of MPS IVA in those countries were estimated to be between 0.14 and 0.45 cases in 100,000 live births.⁸⁻¹⁰ In Taiwan, the birth incidence for all MPS cases was 2.04 per 100,000 live births investigated from

January 1984 to December 2004,¹¹ with MPS IV incidence estimated at 0.33 per 100,000 live births, accounting for 16% of all MPS cases in Taiwan.

Recently, several experimental and approved treatments have been reported for some of MPS subtypes and these include haematopoietic stem cell transplantation,^{12,13} enzyme replacement therapy (ERT),^{12,14-17} premature stop codon read-through^{18,19} and vector-mediated gene therapy.²⁰⁻²² ERTs are available for MPS I, MPS II, MPS IVA and MPS VI. ERT with recombinant human GALNS (elosulfase alfa) was approved in 2014 and is the first systemic treatment available for patients with MPS IVA.

Optimal benefits from ERT, particularly for MPS IVA patients who suffer from devastating cartilage disease, would require commencement of treatment before the onset of irreversible clinical disease. With the exception of cases where there is a family history of the disease, pre-symptomatic detection of MPS can only be achieved by newborn screening. Recent progress towards newborn screening for LSDs holds promise for early detection.²³⁻²⁵

MPS is diagnosed by a decrease in or loss of enzyme activity, usually involving a fluorescent-tagged artificial substrate such as 4-methylumbelliferone (4MU) or a natural substrate in which a fragment of biological substrate is labelled with a radio-stable isotope.²⁶⁻²⁸ Homogenates of cultured fibroblasts and leukocytes have been widely used for definitive diagnoses of LSDs. The use of dried blood spot (DBS) samples offer several

advantages in terms of cost, transportation and suitability of sample collection from neonates.

We previously reported findings from a pilot study of newborn screening for MPS I in Taiwan using the 4MU fluorescent enzymatic assay and have analyzed more than 67,500 samples since 2008.²³ The 4MU enzymatic assay for GALNS enzyme activity in DBS has not been proven to be consistently successful since 2010.²⁸⁻³¹ Even though the recent study showed that GALNS can be reliably and accurately measured by mass spectrometry in DBS,²⁹ the quality and the stability of the synthesized substrate, as well as the commercialization are all needed to be clarified further. In this study, we reported to conduct a pilot study to determine the utility of the Bio-Plex immunoassay for the quantitation of GALNS protein in DBS as an alternative method used for MPS IVA newborn first-line biochemistry examination in Taiwan. The Bio-Plex immunoassay has many advantages, such as high specificity, high throughput, quantitative assay, and easy-to-use 96-well plate-based suspension analysis system. Similar to enzyme-linked immunosorbent assay (ELISA) (Figure 1), the Bio-Plex assay utilizes antibody-coupled magnetic beads (capture beads) to react and bind first with the antigen (GALNS protein) eluted from the DBS sample. The antigen-antibody complex is then treated by biotinylated detection antibodies and a reporter streptavidin-phycoerythrin conjugate. Fluorescence intensity of the reporter conjugate is then measured to determine GALNS quantities. The reading intensity of the fluorescence is proportional to the amount of GALNS protein in the DBS sample.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PARTICIPANTS AND METHODS

Preparation of DBS samples

DBS samples were obtained according to the National Committee for Clinical Laboratory Standards protocol (NCCLS standard LA4-A4), “Blood Collection on Filter Paper for Neonatal Screening Program”.³²⁻³³ Blood samples were collected by heel puncture on the second day of life. Drops of blood were spotted directly on filter paper (ToYo PKU No. 545, Japan) and dried at room temperature for at least 4 hours. DBS samples were stored at 4°C in zipper-lock plastic bags prior to quantitative analysis of GALNS protein by Bio-Plex immunoassay.

Between December 2013 and November 2015, a total of 7,415 DBS samples were collected from neonates born in the main medical centre and three other branches of MacKay Memorial Hospital in Taiwan. Written informed consents were obtained from the parents prior to the screening process (12MMHIS188 approved by MacKay Memorial Hospital Institutional Review Board). The infant examinees were defined as normal GALNS levels in DBS about 95% of the values lie within two standard deviations. The reference values of GALNS levels in normal infants (n=356) were calculated by using Microsoft Excel 2013, and the Shapiro-Wilk Test of normality was also determined. Eleven DBS samples from confirmed MPS IVA patients without receiving ERT (aged from 4.2~29.0 years old) were used as positive controls to test the method. All the patients were with significant clinical manifestations; particularly systemic skeletal dysplasia

including bone deformities like gibbus, genu valgum and dysostosis multiplex, and all the patients had no symptom of central nervous system involvement.

Assay validation tests

In the study, ten DBS samples obtained from the outpatient clinic recruited non-MPS volunteers were run and calculated for within-run and between-run precisions (Coefficient of Variance; CV %). All the 10 samples were run in 6 consecutive replicates for within-run analysis, and a duplicate analysis of each sample ($n = 10$) was performed on 6 different days sequentially. Additionally, the other EDTA blood samples were collected from non-MPS participants ($n=20$) and pooled, which were used to make a normal control (C1, $n = 20$) and an inactivated control (C2, $n = 20$), in which the inactivated control DBS samples were placed in a 50°C oven for 96 hours to degrade GALNS. These control DBS samples were used for assay quality control.

In this study, control DBS samples were collected and stored in low gas-permeability plastic bags at -30°C until analysis. The precision of the assay was performed to assess the repeatability. In order to ensure the stability and the accuracy of Bio-Plex immunoassay in DBS, the within-run and between-run precisions of DBS controls (C1 and C2) were evaluated. All prepared DBS samples were run in six consecutive replicates for the within-run analysis, while a duplicate analysis of each sample was performed on six different days sequentially for the between-run precision. Recovery analysis was also performed by spiking aqueous GALNS working standard (25.0

µg/L) into EDTA whole blood obtained from the same participants with appropriate ratio in volumes.

Bio-Plex immunoassay workflow

The MPS IVA specific Bio-Plex immunoassay was performed using the Bio-Plex[®] 200 System (Bio-Rad Laboratories, Hercules, CA, USA) as described.^{34, 35} DBSs (3.175 mm diameter) were punched from the DBS samples for GALNS protein elution. Each DBS was transferred to one well in a 96-well plate and eluted overnight (16 hours) at 4°C in 130µL phosphate-saline buffer (0.05% Tween, 20.05% bovine serum albumin, 0.05% γ-globulin and 0.05% sodium azide; pH 7.4). A Bio-Plex Pro[™] Magnetic COOH bead (bead #35; Luminex Corp., Austin, TX, USA) was used in this study. The protein coupling was performed according to the instruction manual issued by Bio-Rad Laboratories. The coupling procedure comprises a two-step carbodiimide reaction. The carboxyl groups on the bead surface were first activated to form an active O-acylisourea intermediate by employing EDAC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride). Then, the intermediate was further formed a more stable ester by treating with S-NHS (N-hydroxysulfosuccinimide), and the stable ester was ready for proceeding the protein coupling reaction. In this study, approximate 6.25×10⁶ carboxylated beads (500 µL) were required and prepared for the coupling reaction. The protein coupling reaction was performed by adding 50 µL (1 mg/mL) capture (primary) GALNS antibody (rabbit polyclonal antibody SAB 1410481, purchased from Sigma-Aldrich Co., St Louis, MO, USA.)

1
2
3 to 450 μ L well-activated bead suspension by gentle agitation on shaker in dark for 2
4
5
6 hours at room temperature.

7
8 DBS eluates (50 μ L) were then incubated with capture beads (2500
9
10 beads/analyte/well), and each with unique spectral address coated with the capture
11
12 GALNS antibody for 16 hours at 4°C. Subsequently, biotin-labelled detection (secondary)
13
14 antibody (133 μ g/L in concentration; mouse monoclonal antibody ab 69957; Abcam,
15
16 Cambridge, UK) were added to the wells and incubated for an additional 2 hours. Free
17
18 capture antibodies were washed out by filtration using a magnetic plate carrier to
19
20 recover the magnetic beads irrespective of capture antibody coating. The beads were
21
22 then incubated in streptavidin–phycoerythrin solution (PE; 1.2 mg/L, 50 μ L/well) at
23
24 room temperature for 30 minutes. After gentle removal of the supernatant from the
25
26 wells, the beads were resuspended in phosphate-saline buffer (125 μ L/well). Specificity
27
28 of antibodies to GALNS protein was verified by performing dot-blot assay and western
29
30 blotting,³⁶⁻³⁹ and the results showed that the specificities of Ag-Ab reactions were good
31
32 and satisfactory (Figure 2). In the Figure 2B, the rabbit GALNS polyclonal and the mouse
33
34 monoclonal antibodies reacted with a full-length human GALNS protein (1 a.a. ~ 522
35
36 a.a.), and the results showed distinct bands of approximately 58 kDa precursor
37
38 (predicted molecular weight) and 40 kDa mature polypeptides in the cell homogenates
39
40 from the wild type by western blotting.
41
42
43
44
45
46
47
48
49
50

51
52 Fluorescence intensity of the beads was determined using the Bio-Plex Protein
53
54 Array System with the Bio-Plex Manager 3.1 software (Bio-Rad, Hercules, CA, USA). The
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

amounts of fluorescence sorting detected by YAG laser with wavelengths of 532 (exciting) and 580 nm (emission) was proportional to the quantity of GALNS protein (expressed as $\mu\text{g/L}$).

Calibration curve

Fresh-made working calibrators were prepared by serial dilutions of GALNS stock solution (1 mg/mL). The human recombinant GALNS protein was purchased from R&D Systems, Inc. (Minneapolis, MN, USA), and the final concentrations of working standards were 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, and 0.39 $\mu\text{g/L}$. Biotin was used as a blank. The GALNS calibration curve (fluorescence intensity against the logarithm of concentrations) was made and showed linear between the concentrations of 0.39 and 12.5 $\mu\text{g/L}$ of GALNS working standards, whereas it illustrated non-linear above the concentrations of 25 $\mu\text{g/L}$ according to the Logistic 5-PL model. The regression analysis (r^2) of the calibration curve (fluorescence reading versus concentrations of GALNS calibrations) was excellent ($r^2 = 0.991$). The correlation of observed versus expected results was 0.999855.

RESULTS

Precision and validation of Bio-Plex immunoassay for GALNS quantitation

A total of ten samples were run and calculated for within-run and between-run precisions (coefficient of variance %; CV%). The within-run and between-run precisions of DBS Bio-Plex immunoassay were 10.74% and 9.37%, respectively. In order to ensure the stability and the accuracy of Bio-Plex immunoassay in DBS, the within-run and between-run precisions of control DBSs (C1 and C2) were also evaluated. The within-run and between-run of C1 and C2 were 7.74% and 9.07%, as well as 6.82% and 12.42%, respectively. The averaged quantities of GALNS were 14.09 ± 3.43 $\mu\text{g/L}$ for C1 and 6.58 ± 1.15 $\mu\text{g/L}$ for C2. The recovery of GALNS using Bio-Plex Immunoassay was excellent, about 94.3%. The validation of Bio-Plex immunoassay for GALNS quantitation was confirmed that the method was capable of meeting the requirements set on it. The sensitivity of the test was good, and the detectable level was as low as 0.39 $\mu\text{g/L}$; in addition, fine specificity of the test was also noted which revealed clear identity from the result analyzed by western blotting. Either capture or detection antibody showed high specificity to the GALNS antigen. For the cross-reactivity of the test, it was not required to be measured due to the single test (single target) performed in this study. There were no significant effects of the matrix observed in this test because of the use of the same phosphate-saline buffer when diluting samples for the standard curve.

Quantitation of GALNS in DBSs

Of the 7,415 samples analyzed, 132 (1.78%) samples had GALNS levels below the cut-off value of 13.08 µg/L at the first time of testing. Most of these (n=124) were excluded and results showed normal when the original DBS samples were reanalyzed. Only eight had been recalled for a second DBS collection and repeated the analysis (recall rate = 0.108%). In those, the GALNS quantities were all greater than 8.30 µg/L (the 2nd time of testing). No positive case has been reported so far in this study.

The reference values of GALNS levels in DBS samples using Bio-Plex immunoassay were 8.30-27.43 µg/L, with a mean of 17.86±4.78 µg/L (Figure 3). Sampling to determine the reference values of GALNS in newborn controls showed a 5,000 samples simulation (Shapiro-Wilk Test, p=0.538) (Figure 4). In confirmed MPS IVA patients who did not receive ERT (n=11), the GALNS quantities were almost near to the lower limit of detection (< 0.39 µg/L) that were far below those of 5% of unaffected control. The GALNS quantities in carrier parents identified from two confirmed MPS IVA patients (n=3) were between 12.34 and 16.53 µg/L (14.17±1.52 µg/L), which were all situated within the normal reference values.

Proposed algorithm for MPS IVA newborn screening

Based on our findings, we propose a diagnostic algorithm for newborn first-line screening for MPS IVA as described in Figure 5. Two levels of testing of the original DBS sample were proposed to rule out the false positive results, particularly in carriers. The cut-off values of the 1st time and the 2nd time of testing were determined according to

the mean and standard deviation (SD) method (Mean \pm SD). In order to reduce the numbers of false-positive cases, the cut-off values of the 1st time and the 2nd time of testing were set at minus 1SD and 2SD from the mean value, respectively. The cut-off level of GALNS quantity in DBS using Bio-Plex immunoassay was 13.08 μ g/L for the first time and 8.30 μ g/L for the second time of testing. Infants who had GALNS level below the cut-off point of 8.30 μ g/L were likely to be the highly suspicious cases and should be recalled for a second DBS sample collection. The application of the first time of testing was used to rule out the false positive samples from the highly suspicious cases, including the carriers. For the second time of testing and the recall, the cut-off value was set even narrow in cut-off value in order to separate strictly the affected infants from the healthy individuals. Confirmative diagnoses including leukocyte enzymatic assay and molecular DNA analysis should be performed further regarding the significant reduction of GALNS level being detected by the second time of testing.

DISCUSSION

Currently, there is no general consensus for the method used for MPS IVA newborn screening. Multiplex assays for quantitative measurement of GALNS activity using tandem mass spectrometry have been developed and reported since 2010;²⁹⁻³¹ however, the 4MU enzymatic assay has not been applied widely due to the stability of the synthesized substrate. Besides, GALNS activity and/or GAG biomarkers, particularly the keratan sulfate in blood, urine, or even DBS, can be detected quantitatively using tandem mass spectrometry method, and have shown to be applicable for MPS IVA newborn screening and the prognostic assessment following ERT.⁴⁰⁻⁴² However, the validation of clinical application, particularly for MPS IVA newborn screening purpose, is still uncertain and controversial. Besides, a fluorometric method had been reported by Camelier et al.,²⁸ that could be also considered for screening of MPS IVA; but there was no data demonstrated that microplate-based fluorescence analysis for the detection of MPS IVA in dried blood samples was reliable and practicable. In this study, an alternative method, the Bio-Plex immunoassay measuring GALNS protein in DBS, is proposed and it can be another choice to be adopted for MPS IVA first-line screening purpose. The method is with high sensitivity and high specificity which is compulsory for the development and implementation of newborn screening. Several similar immunoassays like immune-quantification assay, immune-capture method and time-resolved fluorometry with the DELFIA method had been developed to screen populations for lysosomal storage disorders (LSD), including MPS.⁴³⁻⁴⁶ However, the experimental

1
2
3 applications and diagnostic purposes of LSD are different. The principle of immune-
4
5 quantification assay is similar with the method we presented in this study, which can
6
7 accurately quantify lysosomal proteins in DBS.⁴⁴
8
9

10
11
12 There were many issues raised by using immunoassay for LSD screening and
13
14 diagnostic purpose, for instance, the stability of protein level in DBS? protein level
15
16 changing through the life? and protein level correlated with clinical severity? According
17
18 to literatures reported,^{28, 43} the LSD enzyme activities in DBS decreased notably when
19
20 DBS samples stored under different temperatures like 4°C or room temperature, but
21
22 protein quantity will not be affected significantly. In order to verify any difference in the
23
24 amount of GALNS protein by age, we had collected both plasma and DBS samples from
25
26 34 unaffected control in variety of ages, in which 3 age groups were divided including
27
28 group 1 (< 2 years old; n=9), group 2 (2-17 years old; n=12), and group 3 (over 18 years
29
30 old; n=13). All the samples were performed measuring GALNS protein based on the
31
32 same method described above. From the results both found in plasma and DBS samples
33
34 we obtained, there were no significant differences between group 1 and group 2, as well
35
36 as between group 2 and group 3, whereas the results showed small bio-statistic
37
38 differences ($p<0.05$) between group 1 and group 3 (data not shown). The conclusion is
39
40 the amount of GALNS protein is changing through the life, but not very noticeable, and
41
42 the changing of protein level in different age groups will not influence the judgment of
43
44 attenuated phenotype by using Bio-Plex immunoassay for measuring GALNS protein
45
46 under this circumstance. Whether or not the protein level correlates with clinical
47
48
49
50
51
52
53
54
55
56

1
2
3 severity? The prediction of clinical severity with a single marker is somewhat limited.
4
5
6 Combined markers including immune-detectable protein and enzyme activity are
7
8 partially predictive of clinical severity.^{44, 45} Many research evidences revealed that the
9
10 effect of GALNS gene mutations on the GALNS tertiary structure was existent that
11
12 indicated a good correlation among protein level, residual activity, and clinical
13
14 phenotype.³⁶⁻³⁹
15
16
17
18

19
20 The overall recall rate of the method was less than 0.108%. The results suggest
21
22 that the Bio-Plex immunoassay is practicable for MPS IVA newborn first-line screening
23
24 purpose due to the rational percentage of false-positive cases. The only concerned
25
26 query we raised for Bio-Plex immunoassay is the false-negative results that may be
27
28 happened due to the production of enzymatic non-functional protein. According to
29
30 literature reported,³⁶ most GALNS mutations identified were point mutations,
31
32 particularly the missense mutation, and small deletions. Transient expression analysis of
33
34 some mutations showed deficiency or low residual GALNS activity due to nonsense
35
36 codon in the transcribed mRNA and thus the protein to be incorrectly translated. Results
37
38 also revealed that the configuration of GALNS protein might be distinctly changed
39
40 because of the destruction of hydrophobic core, salt bridge removal, and modification
41
42 of active site.^{36, 47-48} Based on the above evidences, false negative results would be
43
44 happened, but should be very rare. Additionally, a crucial point of false negative result
45
46 that needs to be concerned by performing this method is, when patients have large
47
48 deletions on an area where there is no epitope, neither the primary nor the reporter
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 GALNS antibodies would not bind on the GALNS antigen, and the GALNS quantity will be
4
5 very low or non-detectable. In this study, we used the rabbit GALNS polyclonal antibody
6
7 (the primary antibody) and the mouse GALNS monoclonal antibody (the reporter
8
9 antibody) that all showed satisfactory specificity to the protein by performing western
10
11 blotting. The rabbit GALNS polyclonal and the mouse monoclonal antibody reacted with
12
13 a full-length human GALNS protein (1 a.a. ~ 522 a.a.), any variations of the gene may
14
15 change the correct amino acid sequence and thus alter the configuration either at the
16
17 active site or the surface of the protein structure. It may not be detectable by using
18
19 immunoassay if the change of protein molecule is distinct.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONCLUSION

To date, very few methods for MPS IVA newborn screening have been reported and none have been clinically adopted. The Bio-Plex immunoassay proposed in this pilot study is a reliable, specific, validated, simple and cost-effective method for measuring GALNS protein in DBS and has the potential to be adopted for MPS IVA newborn screening purpose. The cost of this technique (per sample) is about 3.27 US\$ which is lower than that of developing a tandem mass spectrometry method for MPS type IVA (about 6.39 US\$) provided by one of the Newborn Screening Center in Taiwan. More collaborating with other newborn screening centres in Taiwan are required to confirm the validation of the method that provides appropriate methodology to screen out more suspicious patients to enable early diagnosis and treatment before the onset of irreversible symptoms.

ACKNOWLEDGEMENTS

All authors have disclosed potential conflicts of interest and all authors have read the journal's policy on conflicts of interest and the journal's authorship agreement. The authors express their sincere thanks to the staff of the Department of Clinical Laboratory and the Department of Pediatrics at MacKay Memorial Hospital for the collection of samples. This study was supported by the research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-105-2628-B-195-001-MY3, MOST-105-2314-B-195-013, MOST-104-2314-B-195-019, and MOST-102-2314-B-195-006) and Mackay Memorial Hospital (MMH-103-13 and MMH-103-115). The writing assistance was provided by Stefanie Chuah, from Mudskipper Shanghai Ltd, funded by BioMarin.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHORS’ CONTRIBUTIONS:

Dr. Chih-Kuang Chuang and Dr. Hsiang-Yu Lin are equal contributors, and participated in this pilot study design, immunoassay development by using dried blood spot filter paper, statistical analysis, data interpretation, and drafting of the manuscript. Dr. Shuan-Pei Lin performed acquisition and interpretation of the data, as well as helped to revise the manuscript. Mr. Tuan-Jen Wang and Sung-Fa Huang coordinated and supervised data collection at Taipei MacKay Memorial Hospital and another three branch hospitals in Taiwan, and performed Bio-Plex immunoassay and data collection. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Funding Source: This study was supported by research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-105-2628-B-195-001-MY3, MOST-105-2314-B-195-013, MOST-104-2314-B-195-019, and MOST-102-2314-B-195-006) and Mackay Memorial Hospital (MMH-103-13 and MMH-103-115).

Financial Disclosure: The authors have no financial relationships relevant to this article to disclose.

Competing interests: None declared.

Patient consent: Written informed consents obtained.

Ethics approval MacKay Memorial Hospital (12MMHIS188).

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: No additional data are available.

Open Access: This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their

derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

For peer review only

REFERENCES

1. Neufeld E and Muenzer J 2001. The mucopolysaccharidoses. In C. Scriver, A. Beaudet, W. Sly, and D. Valle, editors The metabolic and molecular bases of inherited disease, 8th ed. McGraw-Hill, New York, USA. 3421-3452.

2. Montano AM, Tomatsu S, Gottesman GS, et al. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007; 30(2):165-174.

3. Wood TC, Harvey K, Beck M, et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013; 36(2):293-307.

4. Lin HY, Chuang CK, Chen MR, et al. Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. Orphanet J Rare Dis. 2014; 9:21.

5. Besley GTN and Wraith JE. Lysosomal disorders. Current Paediatrics. 1997; 7(2):128-134.

6. Wraith JE. Mucopolysaccharidoses. Current Paediatrics. 1996; 6(2):74-79.

7. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997; 101(3):355-358.

8. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. *J Inherit Metab Dis*. 2005; 28(6):1011-1017.
9. Jurecka A, Lugowska A, Golda A, et al. Prevalence rates of mucopolysaccharidoses in Poland. *J Appl Genet*. 2015; 56(2):205–210.
10. Ben TH, Tebib N, Azzouz H, et al. Incidence of mucopolysaccharidoses in Tunisia. *Tunis Med*. 2009; 87(11):782–785.
11. Lin HY, Lin SP, Chuang CK, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. *Am J Med Genet A*. 2009; 149A (5):960–964.
12. Patel P, Suzuki Y, Tanaka A, et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter Syndrome. *Mol Genet Metab Rep*. 2014; 1:184–196.
13. Tanjuakio J, Suzuki Y, Patel P, et al. Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation. *Mol Genet Metab*. 2015; 114(2):161–169.
14. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). *J Pediatr*. 2004; 144(5):581–588.

1
2
3 15. Tomatsu S, Alméciga-Díaz C, Barbosa H, et al. Therapies of mucopolysaccharidosis
4
5 IVA (Morquio A syndrome). Expert Opin Orphan Drugs. 2013; 1(10):805–818.
6
7
8
9
10 16. Decker C, Yu ZF, Giugliani R, et al. Enzyme replacement therapy for
11
12 mucopolysaccharidosis VI: Growth and pubertal development in patients treated
13
14 with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med.
15
16 2010; 3(2):89–100.
17
18
19
20
21 17. Tomatsu S, Montano AM, Oikawa H, et al. Enzyme replacement therapy in newborn
22
23 mucopolysaccharidosis IVA mice: early treatment rescues bone lesions? Mol Genet
24
25 Metab. 2015; 114(2):195–202.
26
27
28
29
30 18. Brooks DA, Muller VJ, Hopwood JJ. Stop-codon read-through for patients affected
31
32 by a lysosomal storage disorder. Trends Mol Med. 2006; 12(8):367–373.
33
34
35
36 19. Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA. alpha-L-
37
38 iduronidase premature stop codons and potential read-through in
39
40 mucopolysaccharidosis type I patients. J Mol Biol. 2004; 338(3):453–462.
41
42
43
44 20. Sands MS and Haskins ME. CNS-directed gene therapy for lysosomal storage
45
46 diseases. Acta Paediatr Suppl. 2008; 97(457):22–27.
47
48
49
50
51 21. Di Domenico C, Villani G, Di Napoli D, et al. Intracranial gene delivery of LV-NAGLU
52
53 vector corrects neuropathology in murine MPS IIIB. Am J Med Genet A. 2009; 149A
54
55

(6):1209–1218.

22. Cearley CN and Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. *J Neurosci*. 2007; 27(37):9928–9940.
23. Lin SP, Lin HY, Wang TJ, et al. A pilot newborn screening program for mucopolysaccharidosis type I in Taiwan. *Orphanet J Rare Dis*. 2013; 8: 147.
24. Scott CR, Elliott S, Buroker N, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. *J Pediatr*. 2013; 163(2):498–503.
25. Ruijter GJ, Goudriaan DA, Boer AM, et al. Newborn screening for hunter disease: a small-scale feasibility study. *JIMD Rep*. 2014; 14: 23–27.
26. Van Diggelen OP, Zhao H, Kleijer WJ, et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A. (MPS IV A). *Clin Chim Acta* 1990;187:131–40.
27. Tylki-Szymanska A, Czartoryska B, Bunge S, et al. Clinical, biochemical and molecular findings in a two-generation Morquio A family. *Clin Genet* 1998;53:369–74.

28. Camelier MV, Burin MG, De Mari J, Vieira TA, Marasca G, Giugliani R. Practical and reliable enzyme test for the detection of mucopolysaccharidosis IVA (Morquio Syndrome type A) in dried blood samples. Clin Chim Acta. 2011 Sep 18;412(19-20):1805-8.

29. Kumar AB, Masi S, Ghomashchi F, et al. Tandem Mass Spectrometry Has a Larger Analytical Range than Fluorescence Assays of Lysosomal Enzymes: Application to Newborn Screening and Diagnosis of Mucopolysaccharidoses Types II, IVA, and VI. Clin Chem. 2015; 61: 1363-71.

30. Duffey TA, Khaliq T, Scott CR, et al. Design and synthesis of substrates for newborn screening of Maroteaux-Lamy and Morquio A syndromes. Bioorg Med Chem Lett. 2010; 20: 5994–5996.

31. Khaliq T, Sadilek M, Scott CR, et al. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis IVA. Clin Chem. 2011; 57: 128–131.

32. National Committee for Clinical Laboratory Standards (NCCLS). Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard-Fourth Edition, NCCLS document LA4-A4. 2003. 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, National Committee for Laboratory Standards.

33. De Jesus V, Zhang XK, Keutzer J, et al. Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage

disorders. Clin Chem. 2009; 55(1):158–164.

34. Meikle PJ, Grasby DJ, Dean CJ, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab. 2006; 88(4):307–314.
35. Parkinson-Lawrence EJ, Muller VJ, Hopwood JJ, et al. N-acetylgalactosamine-6-sulfatase protein detection in MPS IVA patient and unaffected control samples. Clin Chim Acta. 2007; 377(1-2):88–91.
36. Sukegawa K, Nakamura H, Kato Z, et al. Biochemical and structural analysis of missense mutations in N-acetylgalactosamine-6-sulfate sulfatase causing mucopolysaccharidosis IVA phenotypes. Hum Mol Genet. 2000 May 22;9(9):1283-90.
37. Montañó AM, Sukegawa K, Kato Z, et al. Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase. J Inherit Metab Dis. 2007 Oct;30(5):758-67.
38. Tomatsu S, Montañó AM, Nishioka T, et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum Mutat. 2005 Dec;26(6):500-12.

39. Tomatsu S, Gutierrez M, Nishioka T, et al. Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase. Hum Mol Genet. 2005 Nov 15;14(22):3321-35.

40. Tomatsu S, Fujii T, Fukushi M, et al. Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab. 2013; 110(1-2):42–53.

41. Tomatsu S, Kubaski F, Sawamoto K, et al. Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry. Nihon Masu Sukuriningu Gakkai Shi. 2014; 24: 19–37.

42. Tomatsu S, Shimada T, Mason RW, et al T. Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. J Anal Bioanal Tech. 2014 Mar 1; 2014(Suppl 2): 006

43. Tan MA, Dean CJ, Hopwood JJ, et al. Diagnosis of metachromatic leukodystrophy by immune quantification of arylsulphatase A protein and activity in dried blood spots. Clin Chem. 2008; 54(11):1925-7.

44. Fuller M, Tucker JN, Lang DL, et al. Screening patients referred to a metabolic clinic for lysosomal storage disorders. J Med Genet. 2011; 48(6):422-5.

45. Parkinson-Lawrence E, Fuller M, Hopwood JJ, et al. Immunochemistry of lysosomal storage disorders. Clin Chem. 2006; 52(9):1660-8.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
46. Fuller M, Brooks DA, Evangelista M, et al. Prediction of neuropathology in mucopolysaccharidosis I patients. *Mol Genet Metab*. 2005; 84(1):18-24.
47. Bond CS, Clements PR, Ashby SJ, et al. Structure of a human lysosomal sulfatase. *Structure*. 1997; 5: 277-89.
48. Lukatela G, Krauss N, Theis K, et al. Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. *Biochemistry*. 1998; 37: 3654-64.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends


Figure 1. Schematic representation of the Bio-Plex immunoassay. The anti-GALNS antibody-coated magnetic beads (capture beads) reacts and binds with GALNS protein from the DBS sample then reacts with biotininated detection antibodies.

Figure 2. The specificities of capture (primary) and detection (secondary) antibodies to antigen (GALNS) have been assured by employing dot-blotting assays (A) and western blotting (B). Both results showed good specificity of this method. Either capture (SAB 1410481; 1:1000) or detection antibody (abcam 69957; 1:1000) showed high specificity to the GALNS antigen. By treating with anti-GALNS antibody, the 58 kDa precursor and 40 kDa mature polypeptides were observed in the wild-type human white blood cell homogenates. The loading control of molecular weight markers are indicated on the left.

Figure 3. The GALNS concentrations (ranges) in dried blood spots from normal control ($17.86 \pm 4.78 \mu\text{g/L}$, $n=356$), carriers ($14.17 \pm 1.52 \mu\text{g/L}$, $n=3$) and confirmed MPS IVA patients ($0.88 \pm 0.19 \mu\text{g/L}$, $n=11$).

Figure 4. Sampling to determine the reference values of GALNS in newborn controls showed normal distribution (5,000 samples, Shapiro-Wilk Test, $p=0.354$).


Figure 5. A diagnostic algorithm for MPS IVA newborn screening test.

Figure 1.

Schematic representation of the Bio-Plex immunoassay. The anti-GALNS antibody-coated magnetic beads (capture beads) reacts and binds with GALNS protein from the DBS sample then reacts with biotininated detection antibodies.


148x80mm (300 x 300 DPI)

Figure 2.



The specificities of capture (primary) and detection (secondary) antibodies to antigen (GALNS) have been assured by employing dot-blotting assays (A) and western blotting (B). Both results showed good specificity of this method. Either capture (SAB 1410481; 1:1000) or detection antibody (abcam 69957; 1:1000) showed high specificity to the GALNS antigen. By treating with anti-GALNS antibody, the 58 kDa precursor and 40 kDa mature polypeptides were observed in the wild-type human white blood cell homogenates. The loading control of molecular weight markers are indicated on the left.


134x180mm (300 x 300 DPI)

Figure 3.

The GALNS concentrations (ranges) in dried blood spots from normal control ($17.86 \pm 4.78 \mu\text{g/L}$, $n=356$), carriers ($14.17 \pm 1.52 \mu\text{g/L}$, $n=3$) and confirmed MPS IVA patients ($0.88 \pm 0.19 \mu\text{g/L}$, $n=11$).

96x82mm (300 x 300 DPI)

Figure 4.




Sampling to determine the reference values of GALNS in newborn controls showed normal distribution (5,000 samples, Shapiro-Wilk Test, $p=0.354$).

108x71mm (300 x 300 DPI)

Figure 5.

Proposed algorithm for MPS IVA newborn screening



A diagnostic algorithm for MPS IVA newborn screening test.

170x199mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract Page # 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page # 3, 4
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page # 6,7, 8
Objectives	3	State specific objectives, including any prespecified hypotheses Page # 6,7, 8
Methods		
Study design	4	Present key elements of study design early in the paper Page # 8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page # 9, 10
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants Page # 9
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page # 9-11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page # 10-12
Bias	9	Describe any efforts to address potential sources of bias Page # 9-12
Study size	10	Explain how the study size was arrived at Page # 9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page # 11-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page # 10-13
		(b) Describe any methods used to examine subgroups and interactions Page # 10-11
		(c) Explain how missing data were addressed
		(d) If applicable, describe analytical methods taking account of sampling strategy Page # 11-13
		(e) Describe any sensitivity analyses Page # 10, 13
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page # 14-15
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram Page # 15-16
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page # 14-16
		(b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures Page # 14-16
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Page # 14-16

		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Page # 14-16
Discussion		
Key results	18	Summarise key results with reference to study objectives Page # 17, 18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page # 18, 19
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page # 17-20
Generalisability	21	Discuss the generalisability (external validity) of the study results Page # 17-21
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page # 1, 22

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Bio-Plex immunoassay measuring the quantity of lysosomal N-acetylgalactosamine-6-sulfatase protein in dried blood spots for the screening of mucopolysaccharidosis IVA in newborn: a pilot study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014410.R2
Article Type:	Research
Date Submitted by the Author:	25-May-2017
Complete List of Authors:	Chuang, Chih-Kuang; Mackay Memorial Hospital, Departments of Medical Research; Mackay Memorial Hospital, Lin, Hsiang-Yu; Mackay Memorial Hospital, Pediatrics Wang, Tuan-Jen ; Mackay Memorial Hospital, Departments of Medical Research Huang, Sung-Fa ; Mackay Memorial Hospital, Departments of Medical Research Lin, Shuan-Pei; Mackay Memorial Hospital, Department of Pediatrics
Primary Subject Heading:	Genetics and genomics
Secondary Subject Heading:	Genetics and genomics, Diagnostics, Paediatrics
Keywords:	mucopolysaccharidosis IVA, lysosomal storage disorder, N-acetylgalactosamine-6-sulfatase, newborn screening, dried blood spot, Bio-Plex immunoassay

SCHOLARONE™
Manuscripts

Bio-Plex immunoassay measuring the quantity of lysosomal N-acetylgalactosamine-6-sulfatase protein in dried blood spots for the screening of mucopolysaccharidosis IVA in newborn: a pilot study

Chih-Kuang Chuang^{†1,4,5}, Hsiang-Yu Lin^{†1,2,6,7}, Tuan-Jen Wang³, Sung-Fa Huang³, and Shuan-Pei Lin^{1,2,7,8*}

Affiliations: ¹Division of Genetics and Metabolism, Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan; ²Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan; ³Department of Laboratory Medicine, Mackay Memorial Hospital, Taipei, Taiwan; ⁴Institute of Biotechnology, National Taipei University of Technology, Taipei, Taiwan; ⁵College of Medicine, Fu-Jen Catholic University, Taipei, Taiwan; ⁶Mackay Junior College of Medicine, Nursing and Management, Taipei, Taiwan; ⁷Department of Medicine, Mackay Medical College, New Taipei City, Taiwan; ⁸Department of Infant and Child Care, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.

[†]Equal contributors

Disclosure/Conflict of Interest: The authors have no conflicts of interest relevant to this article to disclose.

Funding Source: This study was supported by research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-102-2314-B-195-006, MOST-104-2314-B-195-019, MOST-105-2628-B-195-001-MY3, and MOST-105-2314-B-195-013) and Mackay Memorial Hospital (MMH-103-13 and MMH-103-115).

Financial Disclosure: The authors have no financial relationships relevant to this article to disclose.

***Address correspondence to:** Shuan-Pei Lin, MD, Departments of Pediatrics and Medical Research, MacKay Memorial Hospital, No. 92, Sec. 2, Chung-Shan N. Rd., Taipei 10449, Taiwan. [zsplin14@gmail.com], 886-2-25433535 ext. 3089.

Abbreviations

MPS, mucopolysaccharidosis;

GALNS, N-acetylgalactosamine-6-sulfatase;

LSDs, lysosomal storage disorders;

GAGs, glycosaminoglycans;

ERT, enzyme replacement therapy;

4MU, 4-Methylumbelliferone;

DBS, dried blood spot;

ELISA, enzyme-linked immunosorbent assay;

CV%, Coefficient of Variance;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective: Mucopolysaccharidosis (MPS) IVA (Morquio syndrome A) is an autosomal recessive lysosomal storage disorder caused by the deficiency of N-acetylgalactosamine-6-sulfatase (GALNS) resulting in excessive lysosomal storage of keratan sulfate. Treatments for MPS IVA have recently become available with optimal outcomes associated with early diagnosis and treatment which can be achieved by newborn screening.

Design: Newborn screening program for MPS IVA pilot study.

Setting: Taipei MacKay Memorial Hospital (MMH), and another 3 branch hospitals in Taiwan.

Participants: A total of 7,415 newborns were born in 4 branch hospitals of MMH and had joined the MPS IVA newborn screening programme. Written informed consents were obtained from parents prior to the screening process (12MMHIS188 approved by MacKay Memorial Hospital Institutional Review Board).

Outcome measures: An alternative newborn screening method for MPS IVA has been performed. Screening involved measuring the quantity of GALNS in dried blood spot (DBS) from newborn infants using the Bio-Plex immunoassay. The amount of fluorescence sorting detected by YAG laser was proportional to the quantity of GALNS protein.

Results: Of the 7,415 neonates analyzed, eight infants whose GALNS levels were below the cut-off value of 8.30 µg/L had been recalled for a second DBS collection. The reference values were 8.30-27.43 µg/L. In confirmed MPS IVA patients (n=11), the GALNS quantities were far below 5% of the normal population.

Conclusion: The Bio-Plex immunoassay is a validated method used for measuring GALNS protein in DBS and has the potential to be adopted for MPS IVA newborn screening study design.

Trial registration number: 12MMHIS188 approved by MacKay Memorial Hospital Institutional Review Board.

Key words: mucopolysaccharidosis IVA, lysosomal storage disorder, N-acetylgalactosamine-6-sulfatase, newborn screening, dried blood spot, Bio-Plex immunoassay.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- The Bio-Plex immunoassay is a well-established, feasible method used for measuring GALNS protein in DBS and has the potential to be adopted for MPS IVA newborn screening study design.
- The early diagnosis of MPS IVA in infantile period is valuable, preventable, and treatable.
- No positive case has been found is the limitation of this study.

INTRODUCTION

Mucopolysaccharidoses (MPSs), a group of rare genetic diseases known as lysosomal storage disorders (LSDs), are caused by the deficiency of enzymes that catalyze the stepwise degradation of glycosaminoglycans (GAGs). Mucopolysaccharidosis IVA (MPS IVA, Morquio syndrome A; OMIM#253000) is a disease characterized by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase (GALNS; EC 3.1.6.4). This deficiency leads to excessive lysosomal storage of keratan sulphate and chondroitin-6-sulfate resulting in devastating manifestations, such as systemic skeletal dysplasia, short stature, joint abnormalities that limit mobility and endurance, malformation of the thorax, which impairs respiratory function, odontoid hypoplasia and ligamentous laxity which causes cervical spinal instability and potentially cord compression. Other symptoms of MPS IVA include hearing loss, corneal clouding and valvular heart disease.¹⁻⁴ Initial symptoms often present during the first 5 years of life depending on disease severity or age of diagnosis.

Few studies have investigated the incidence (or prevalence) of MPS. The overall incidence of MPS was estimated to be 1 in 10,000–25,000 births in Europe.^{1, 5-6} The highest incidence of MPS IVA was reported in Northern Ireland with a rate of 1.31 in 100,000 live births,⁷ which was substantially higher compared with other countries such as Germany, Poland and Tunisia. The birth incidences of MPS IVA in those countries were estimated to be between 0.14 and 0.45 cases in 100,000 live births.⁸⁻¹⁰ In Taiwan, the birth incidence for all MPS cases was 2.04 per 100,000 live births investigated from

January 1984 to December 2004,¹¹ with MPS IV incidence estimated at 0.33 per 100,000 live births, accounting for 16% of all MPS cases in Taiwan.

Recently, several experimental and approved treatments have been reported for some of MPS subtypes and these include haematopoietic stem cell transplantation,^{12,13} enzyme replacement therapy (ERT),^{12,14-17} premature stop codon read-through^{18,19} and vector-mediated gene therapy.²⁰⁻²² ERTs are available for MPS I, MPS II, MPS IVA and MPS VI. ERT with recombinant human GALNS (elosulfase alfa) was approved in 2014 and is the first systemic treatment available for patients with MPS IVA.

Optimal benefits from ERT, particularly for MPS IVA patients who suffer from devastating cartilage disease, would require commencement of treatment before the onset of irreversible clinical disease. With the exception of cases where there is a family history of the disease, pre-symptomatic detection of MPS can only be achieved by newborn screening. Recent progress towards newborn screening for LSDs holds promise for early detection.²³⁻²⁵

MPS is diagnosed by a decrease in or loss of enzyme activity, usually involving a fluorescent-tagged artificial substrate such as 4-methylumbelliferone (4MU) or a natural substrate in which a fragment of biological substrate is labelled with a radio-stable isotope.²⁶⁻²⁸ Homogenates of cultured fibroblasts and leukocytes have been widely used for definitive diagnoses of LSDs. The use of dried blood spot (DBS) samples offer several

1
2
3 advantages in terms of cost, transportation and suitability of sample collection from
4
5 neonates.
6
7

8
9 We previously reported findings from a pilot study of newborn screening for MPS I
10
11 in Taiwan using the 4MU fluorescent enzymatic assay and have analyzed more than
12
13 67,500 samples since 2008.²³ The 4MU enzymatic assay for GALNS enzyme activity in
14
15 DBS has not been proven to be consistently successful since 2010.²⁸⁻³¹ Even though the
16
17 recent study showed that GALNS can be reliably and accurately measured by mass
18
19 spectrometry in DBS,²⁹ the quality and the stability of the synthesized substrate, as well
20
21 as the commercialization are all needed to be clarified further. In this study, we
22
23 reported to conduct a pilot study to determine the utility of the Bio-Plex immunoassay
24
25 for the quantitation of GALNS protein in DBS as an alternative method used for MPS IVA
26
27 newborn first-line biochemistry examination in Taiwan. The Bio-Plex immunoassay has
28
29 many advantages, such as high specificity, high throughput, quantitative assay, and
30
31 easy-to-use 96-well plate-based suspension analysis system. Similar to enzyme-linked
32
33 immunosorbent assay (ELISA) (Figure 1), the Bio-Plex assay utilizes antibody-coupled
34
35 magnetic beads (capture beads) to react and bind first with the antigen (GALNS protein)
36
37 eluted from the DBS sample. The antigen-antibody complex is then treated by
38
39 biotinylated detection antibodies and a reporter streptavidin-phycoerythrin conjugate.
40
41 Fluorescence intensity of the reporter conjugate is then measured to determine GALNS
42
43 quantities. The reading intensity of the fluorescence is proportional to the amount of
44
45 GALNS protein in the DBS sample.
46
47
48
49
50
51
52
53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PARTICIPANTS AND METHODS

Preparation of DBS samples

DBS samples were obtained according to the National Committee for Clinical Laboratory Standards protocol (NCCLS standard LA4-A4), “Blood Collection on Filter Paper for Neonatal Screening Program”.³²⁻³³ Blood samples were collected by heel puncture on the second day of life. Drops of blood were spotted directly on filter paper (ToYo PKU No. 545, Japan) and dried at room temperature for at least 4 hours. DBS samples were stored at 4°C in zipper-lock plastic bags prior to quantitative analysis of GALNS protein by Bio-Plex immunoassay.

Between December 2013 and November 2015, a total of 7,415 DBS samples were collected from neonates born in the main medical centre and three other branches of MacKay Memorial Hospital in Taiwan. Written informed consents were obtained from the parents prior to the screening process (12MMHIS188 approved by MacKay Memorial Hospital Institutional Review Board). The infant examinees were defined as normal GALNS levels in DBS about 95% of the values lie within two standard deviations. The reference values of GALNS levels in normal infants (n=356) were calculated by using Microsoft Excel 2013, and the Shapiro-Wilk Test of normality was also determined. Eleven DBS samples from confirmed MPS IVA patients without receiving ERT (aged from 4.2~29.0 years old) were used as positive controls to test the method. All the patients were with significant clinical manifestations; particularly systemic skeletal dysplasia

including bone deformities like gibbus, genu valgum and dysostosis multiplex, and all the patients had no symptom of central nervous system involvement.

Assay validation tests

In the study, ten DBS samples obtained from the outpatient clinic recruited non-MPS volunteers were run and calculated for within-run and between-run precisions (Coefficient of Variance; CV %). All the 10 samples were run in 6 consecutive replicates for within-run analysis, and a duplicate analysis of each sample ($n = 10$) was performed on 6 different days sequentially. Additionally, the other EDTA blood samples were collected from non-MPS participants ($n=20$) and pooled, which were used to make a normal control (C1, $n = 20$) and an inactivated control (C2, $n = 20$), in which the inactivated control DBS samples were placed in a 50°C oven for 96 hours to degrade GALNS. These control DBS samples were used for assay quality control.

In this study, control DBS samples were collected and stored in low gas-permeability plastic bags at -30°C until analysis. The precision of the assay was performed to assess the repeatability. In order to ensure the stability and the accuracy of Bio-Plex immunoassay in DBS, the within-run and between-run precisions of DBS controls (C1 and C2) were evaluated. All prepared DBS samples were run in six consecutive replicates for the within-run analysis, while a duplicate analysis of each sample was performed on six different days sequentially for the between-run precision. Recovery analysis was also performed by spiking aqueous GALNS working standard (25.0

µg/L) into EDTA whole blood obtained from the same participants with appropriate ratio in volumes.

Bio-Plex immunoassay workflow

The MPS IVA specific Bio-Plex immunoassay was performed using the Bio-Plex[®] 200 System (Bio-Rad Laboratories, Hercules, CA, USA) as described.^{34, 35} DBSs (3.175 mm diameter) were punched from the DBS samples for GALNS protein elution. Each DBS was transferred to one well in a 96-well plate and eluted overnight (16 hours) at 4°C in 130µL phosphate-saline buffer (0.05% Tween, 20.05% bovine serum albumin, 0.05% γ-globulin and 0.05% sodium azide; pH 7.4). A Bio-Plex Pro[™] Magnetic COOH bead (bead #35; Luminex Corp., Austin, TX, USA) was used in this study. The protein coupling was performed according to the instruction manual issued by Bio-Rad Laboratories. The coupling procedure comprises a two-step carbodiimide reaction. The carboxyl groups on the bead surface were first activated to form an active O-acylisourea intermediate by employing EDAC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride). Then, the intermediate was further formed a more stable ester by treating with S-NHS (N-hydroxysulfosuccinimide), and the stable ester was ready for proceeding the protein coupling reaction. In this study, approximate 6.25×10⁶ carboxylated beads (500 µL) were required and prepared for the coupling reaction. The protein coupling reaction was performed by adding 50 µL (1 mg/mL) capture (primary) GALNS antibody (rabbit polyclonal antibody SAB 1410481, purchased from Sigma-Aldrich Co., St Louis, MO, USA.)

1
2
3 to 450 μ L well-activated bead suspension by gentle agitation on shaker in dark for 2
4
5
6 hours at room temperature.

7
8 DBS eluates (50 μ L) were then incubated with capture beads (2500
9
10 beads/analyte/well), and each with unique spectral address coated with the capture
11
12 GALNS antibody for 16 hours at 4°C. Subsequently, biotin-labelled detection (secondary)
13
14 antibody (133 μ g/L in concentration; mouse monoclonal antibody ab 69957; Abcam,
15
16 Cambridge, UK) were added to the wells and incubated for an additional 2 hours. Free
17
18 capture antibodies were washed out by filtration using a magnetic plate carrier to
19
20 recover the magnetic beads irrespective of capture antibody coating. The beads were
21
22 then incubated in streptavidin–phycoerythrin solution (PE; 1.2 mg/L, 50 μ L/well) at
23
24 room temperature for 30 minutes. After gentle removal of the supernatant from the
25
26 wells, the beads were resuspended in phosphate-saline buffer (125 μ L/well). Specificity
27
28 of antibodies to GALNS protein was verified by performing dot-blot assay (Figure 2A)
29
30 and western blotting (Figure 2B),³⁶⁻³⁹ and the results showed that the specificities of Ag-
31
32 Ab reactions were good and satisfactory. In the Figure 2B, the rabbit GALNS polyclonal
33
34 and the mouse monoclonal antibodies reacted with a full-length human GALNS protein
35
36 (1 a.a. ~ 522 a.a.), and the results showed distinct bands of approximately 58 kDa
37
38 precursor (predicted molecular weight) and 40 kDa mature polypeptides in the cell
39
40 homogenates from the wild type by western blotting.
41
42
43
44
45
46
47
48
49
50

51
52 Fluorescence intensity of the beads was determined using the Bio-Plex Protein
53
54 Array System with the Bio-Plex Manager 3.1 software (Bio-Rad, Hercules, CA, USA). The
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

amounts of fluorescence sorting detected by YAG laser with wavelengths of 532 (exciting) and 580 nm (emission) was proportional to the quantity of GALNS protein (expressed as $\mu\text{g/L}$).

Calibration curve

Fresh-made working calibrators were prepared by serial dilutions of GALNS stock solution (1 mg/mL). The human recombinant GALNS protein was purchased from R&D Systems, Inc. (Minneapolis, MN, USA), and the final concentrations of working standards were 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, and 0.39 $\mu\text{g/L}$. Biotin was used as a blank. The GALNS calibration curve (fluorescence intensity against the logarithm of concentrations) was made and showed linear between the concentrations of 0.39 and 12.5 $\mu\text{g/L}$ of GALNS working standards, whereas it illustrated non-linear above the concentrations of 25 $\mu\text{g/L}$ according to the Logistic 5-PL model. The regression analysis (r^2) of the calibration curve (fluorescence reading versus concentrations of GALNS calibrations) was excellent ($r^2 = 0.991$). The correlation of observed versus expected results was 0.999855.

RESULTS

Precision and validation of Bio-Plex immunoassay for GALNS quantitation

A total of ten samples were run and calculated for within-run and between-run precisions (coefficient of variance %; CV%). The within-run and between-run precisions of DBS Bio-Plex immunoassay were 10.74% and 9.37%, respectively. In order to ensure the stability and the accuracy of Bio-Plex immunoassay in DBS, the within-run and between-run precisions of control DBSs (C1 and C2) were also evaluated. The within-run and between-run of C1 and C2 were 7.74% and 9.07%, as well as 6.82% and 12.42%, respectively. The averaged quantities of GALNS were 14.09 ± 3.43 $\mu\text{g/L}$ for C1 and 6.58 ± 1.15 $\mu\text{g/L}$ for C2. The recovery of GALNS using Bio-Plex Immunoassay was excellent, about 94.3%. The validation of Bio-Plex immunoassay for GALNS quantitation was confirmed that the method was capable of meeting the requirements set on it. The sensitivity and specificity of the test according to false positives and false negatives in relation with true positives and true negatives were excellent about 100% and 99.89%, respectively. The detectable level was as low as 0.39 $\mu\text{g/L}$; in addition, fine specificity of the immunoassay was also noted which revealed clear identity from the result analyzed by western blotting. Either capture or detection antibody showed high specificity to the GALNS antigen. For the cross-reactivity of the test, it was not required to be measured due to the single test (single target) performed in this study. There were no significant effects of the matrix observed in this test because of the use of the same phosphate-saline buffer when diluting samples for the standard curve.

Quantitation of GALNS in DBSs

Of the 7,415 samples analyzed, 132 (1.78%) samples had GALNS levels below the cut-off value of 13.08 µg/L at the first time of testing. Most of these (n=124) were excluded and results showed normal when the original DBS samples were reanalyzed. Only eight had been recalled for a second DBS collection and repeated the analysis (recall rate = 0.108%). In those, the GALNS quantities were all greater than 8.30 µg/L (the 2nd time of testing). No positive case has been reported so far in this study.

The reference values of GALNS levels in DBS samples using Bio-Plex immunoassay were 8.30-27.43 µg/L, with a mean of 17.86±4.78 µg/L (Figure 3). Sampling to determine the reference values of GALNS in newborn controls showed a 5,000 samples simulation (Shapiro-Wilk Test, p=0.538) (Figure 4). In confirmed MPS IVA patients who did not receive ERT (n=11), the GALNS quantities were almost near to the lower limit of detection (< 0.39 µg/L) that were far below those of 5% of unaffected control. The GALNS quantities in carrier parents identified from two confirmed MPS IVA patients (n=3) were between 12.34 and 16.53 µg/L (14.17±1.52 µg/L), which were all situated within the normal reference values.

Proposed algorithm for MPS IVA newborn screening

Based on our findings, we propose a diagnostic algorithm for newborn first-line screening for MPS IVA as described in Figure 5. Two levels of testing of the original DBS sample were proposed to rule out the false positive results, particularly in carriers. The

cut-off values of the 1st time and the 2nd time of testing were determined according to the mean and standard deviation (SD) method (Mean \pm SD). In order to reduce the numbers of false-positive cases, the cut-off values of the 1st time and the 2nd time of testing were set at minus 1SD and 2SD from the mean value, respectively. The cut-off level of GALNS quantity in DBS using Bio-Plex immunoassay was 13.08 μ g/L for the first time and 8.30 μ g/L for the second time of testing. Infants who had GALNS level below the cut-off point of 8.30 μ g/L were likely to be the highly suspicious cases and should be recalled for a second DBS sample collection. The application of the first time of testing was used to rule out the false positive samples from the highly suspicious cases, including the carriers. For the second time of testing and the recall, the cut-off value was set even narrow in cut-off value in order to separate strictly the affected infants from the healthy individuals. Confirmative diagnoses including leukocyte enzymatic assay and molecular DNA analysis should be performed further regarding the significant reduction of GALNS level being detected by the second time of testing.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Currently, there is no general consensus for the method used for MPS IVA newborn screening. Multiplex assays for quantitative measurement of GALNS activity using tandem mass spectrometry have been developed and reported since 2010;²⁹⁻³¹ however, the 4MU enzymatic assay has not been applied widely due to the stability of the synthesized substrate. Besides, GALNS activity and/or GAG biomarkers, particularly the keratan sulfate in blood, urine, or even DBS, can be detected quantitatively using tandem mass spectrometry method, and have shown to be applicable for MPS IVA newborn screening and the prognostic assessment following ERT.⁴⁰⁻⁴² However, the validation of clinical application, particularly for MPS IVA newborn screening purpose, is still uncertain and controversial. Besides, a fluorometric method had been reported by Camelier et al.,²⁸ that could be also considered for screening of MPS IVA; but there was no data demonstrated that microplate-based fluorescence analysis for the detection of MPS IVA in dried blood samples was reliable and practicable. In this study, an alternative method, the Bio-Plex immunoassay measuring GALNS protein in DBS, is proposed and it can be another choice to be adopted for MPS IVA first-line screening purpose. The method is with high sensitivity and high specificity which is compulsory for the development and implementation of newborn screening. Several similar immunoassays like immune-quantification assay, immune-capture method and time-resolved fluorometry with the DELFIA method had been developed to screen populations for lysosomal storage disorders (LSD), including MPS.⁴³⁻⁴⁶ However, the experimental

1
2
3 applications and diagnostic purposes of LSD are different. The principle of immune-
4
5 quantification assay is similar with the method we presented in this study, which can
6
7 accurately quantify lysosomal proteins in DBS.⁴⁴
8
9

10
11
12 There were many issues raised by using immunoassay for LSD screening and
13
14 diagnostic purpose, for instance, the stability of protein level in DBS? protein level
15
16 changing through the life? and protein level correlated with clinical severity? According
17
18 to literatures reported,^{28, 43} the LSD enzyme activities in DBS decreased notably when
19
20 DBS samples stored under different temperatures like 4°C or room temperature, but
21
22 protein quantity will not be affected significantly. In order to verify any difference in the
23
24 amount of GALNS protein by age, we had collected both plasma and DBS samples from
25
26 34 unaffected control in variety of ages, in which 3 age groups were divided including
27
28 group 1 (< 2 years old; n=9), group 2 (2-17 years old; n=12), and group 3 (over 18 years
29
30 old; n=13). All the samples were performed measuring GALNS protein based on the
31
32 same method described above. From the results both found in plasma and DBS samples
33
34 we obtained, there were no significant differences between group 1 and group 2, as well
35
36 as between group 2 and group 3, whereas the results showed small bio-statistic
37
38 differences ($p<0.05$) between group 1 and group 3 (data not shown). The conclusion is
39
40 the amount of GALNS protein is changing through the life, but not very noticeable, and
41
42 the changing of protein level in different age groups will not influence the judgment of
43
44 attenuated phenotype by using Bio-Plex immunoassay for measuring GALNS protein
45
46 under this circumstance. Whether or not the protein level correlates with clinical
47
48
49
50
51
52
53
54
55
56

1
2
3 severity? The prediction of clinical severity with a single marker is somewhat limited.
4
5
6 Combined markers including immune-detectable protein and enzyme activity are
7
8 partially predictive of clinical severity.^{44, 45} Many research evidences revealed that the
9
10 effect of GALNS gene mutations on the GALNS tertiary structure was existent that
11
12 indicated a good correlation among protein level, residual activity, and clinical
13
14 phenotype.³⁶⁻³⁹
15
16
17
18

19
20 The overall recall rate of the method was less than 0.108%. The results suggest
21
22 that the Bio-Plex immunoassay is practicable for MPS IVA newborn first-line screening
23
24 purpose due to the rational percentage of false-positive cases. The only concerned
25
26 query we raised for Bio-Plex immunoassay is the false-negative results that may be
27
28 happened due to the production of enzymatic non-functional protein. According to
29
30 literature reported,³⁶ most GALNS mutations identified were point mutations,
31
32 particularly the missense mutation, and small deletions. Transient expression analysis of
33
34 some mutations showed deficiency or low residual GALNS activity due to nonsense
35
36 codon in the transcribed mRNA and thus the protein to be incorrectly translated. Results
37
38 also revealed that the configuration of GALNS protein might be distinctly changed
39
40 because of the destruction of hydrophobic core, salt bridge removal, and modification
41
42 of active site.^{36, 47-48} Rivera-Colón et al. reported that most of the mutations (76.4%;
43
44 120/157 mutations) have been identified in the GALNS gene in MPS IVA patients were
45
46 missense mutations leading to a change of a single side chain residue in the protein.
47
48
49 Based on the data reported, GALNS mutations in MPS IVA being mapped to their
50
51
52
53
54
55
56
57
58
59
60

location on the protein showed that most of the mutations (65%; 78/120 mutations) lead to changes in buried residues of the hydrophobic core, and it means that MPS IVA is most often a protein-folding disease. Only 6 mutations (5%) affect active site residues and 32 mutations (27%) that map to surface residues. The GALNS protein fails to fold into its normal configuration, and can lose its normal function.⁴⁹ Based on the above evidences, false negative results would be happened, but should be very rare. Additionally, a crucial point of false negative result that needs to be concerned by performing this method is, when patients have large deletions on an area where there is no epitope, neither the primary nor the reporter GALNS antibodies would not bind on the GALNS antigen, and the GALNS quantity will be very low or non-detectable. In this study, we used the rabbit GALNS polyclonal antibody (the primary antibody) and the mouse GALNS monoclonal antibody (the reporter antibody) that all showed satisfactory specificity to the protein by performing western blotting. The rabbit GALNS polyclonal and the mouse monoclonal antibody reacted with a full-length human GALNS protein (1 a.a. ~ 522 a.a.), any variations of the gene may change the correct amino acid sequence and thus alter the configuration either at the active site or the surface of the protein structure. It may not be detectable by using immunoassay if the change of protein molecule is distinct.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONCLUSION

To date, very few methods for MPS IVA newborn screening have been reported and none have been clinically adopted. The Bio-Plex immunoassay proposed in this pilot study is a reliable, specific, validated, simple and cost-effective method for measuring GALNS protein in DBS and has the potential to be adopted for MPS IVA newborn screening purpose. The cost of this technique (per sample) is about 3.27 US\$ which is lower than that of developing a tandem mass spectrometry method for MPS type IVA (about 6.39 US\$) provided by one of the Newborn Screening Center in Taiwan. More collaborating with other newborn screening centres in Taiwan are required to confirm the validation of the method that provides appropriate methodology to screen out more suspicious patients to enable early diagnosis and treatment before the onset of irreversible symptoms.

ACKNOWLEDGEMENTS

All authors have disclosed potential conflicts of interest and all authors have read the journal's policy on conflicts of interest and the journal's authorship agreement. The authors express their sincere thanks to the staff of the Department of Clinical Laboratory and the Department of Pediatrics at MacKay Memorial Hospital for the collection of samples. This study was supported by the research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-105-2628-B-195-001-MY3, MOST-105-2314-B-195-013, MOST-104-2314-B-195-019, and MOST-102-2314-B-195-006) and Mackay Memorial Hospital (MMH-103-13 and MMH-103-115). The writing assistance was provided by Stefanie Chuah, from Mudskipper Shanghai Ltd, funded by BioMarin.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHORS’ CONTRIBUTIONS:

Dr. Chih-Kuang Chuang and Dr. Hsiang-Yu Lin are equal contributors, and participated in this pilot study design, immunoassay development by using dried blood spot filter paper, statistical analysis, data interpretation, and drafting of the manuscript. Dr. Shuan-Pei Lin performed acquisition and interpretation of the data, as well as helped to revise the manuscript. Mr. Tuan-Jen Wang and Sung-Fa Huang coordinated and supervised data collection at Taipei MacKay Memorial Hospital and another three branch hospitals in Taiwan, and performed Bio-Plex immunoassay and data collection. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Funding Source: This study was supported by research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-105-2628-B-195-001-MY3, MOST-105-2314-B-195-013, MOST-104-2314-B-195-019, and MOST-102-2314-B-195-006) and Mackay Memorial Hospital (MMH-103-13 and MMH-103-115).

Financial Disclosure: The authors have no financial relationships relevant to this article to disclose.

Competing interests: None declared.

Patient consent: Written informed consents obtained.

Ethics approval MacKay Memorial Hospital (12MMHIS188).

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: No additional data are available.

Open Access: This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their

derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

For peer review only

REFERENCES

1. Neufeld E and Muenzer J 2001. The mucopolysaccharidoses. In C. Scriver, A. Beaudet, W. Sly, and D. Valle, editors The metabolic and molecular bases of inherited disease, 8th ed. McGraw-Hill, New York, USA. 3421-3452.

2. Montano AM, Tomatsu S, Gottesman GS, et al. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007; 30(2):165-174.

3. Wood TC, Harvey K, Beck M, et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013; 36(2):293-307.

4. Lin HY, Chuang CK, Chen MR, et al. Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. Orphanet J Rare Dis. 2014; 9:21.

5. Besley GTN and Wraith JE. Lysosomal disorders. Current Paediatrics. 1997; 7(2):128-134.

6. Wraith JE. Mucopolysaccharidoses. Current Paediatrics. 1996; 6(2):74-79.

7. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997; 101(3):355-358.

8. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. *J Inherit Metab Dis*. 2005; 28(6):1011-1017.
9. Jurecka A, Lugowska A, Golda A, et al. Prevalence rates of mucopolysaccharidoses in Poland. *J Appl Genet*. 2015; 56(2):205–210.
10. Ben TH, Tebib N, Azzouz H, et al. Incidence of mucopolysaccharidoses in Tunisia. *Tunis Med*. 2009; 87(11):782–785.
11. Lin HY, Lin SP, Chuang CK, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. *Am J Med Genet A*. 2009; 149A (5):960–964.
12. Patel P, Suzuki Y, Tanaka A, et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter Syndrome. *Mol Genet Metab Rep*. 2014; 1:184–196.
13. Tanjuakio J, Suzuki Y, Patel P, et al. Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation. *Mol Genet Metab*. 2015; 114(2):161–169.
14. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). *J Pediatr*. 2004; 144(5):581–588.

1
2
3 15. Tomatsu S, Alméciga-Díaz C, Barbosa H, et al. Therapies of mucopolysaccharidosis
4
5 IVA (Morquio A syndrome). Expert Opin Orphan Drugs. 2013; 1(10):805–818.
6
7
8
9
10 16. Decker C, Yu ZF, Giugliani R, et al. Enzyme replacement therapy for
11
12 mucopolysaccharidosis VI: Growth and pubertal development in patients treated
13
14 with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med.
15
16 2010; 3(2):89–100.
17
18
19
20
21 17. Tomatsu S, Montano AM, Oikawa H, et al. Enzyme replacement therapy in newborn
22
23 mucopolysaccharidosis IVA mice: early treatment rescues bone lesions? Mol Genet
24
25 Metab. 2015; 114(2):195–202.
26
27
28
29
30 18. Brooks DA, Muller VJ, Hopwood JJ. Stop-codon read-through for patients affected
31
32 by a lysosomal storage disorder. Trends Mol Med. 2006; 12(8):367–373.
33
34
35
36 19. Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA. alpha-L-
37
38 iduronidase premature stop codons and potential read-through in
39
40 mucopolysaccharidosis type I patients. J Mol Biol. 2004; 338(3):453–462.
41
42
43
44 20. Sands MS and Haskins ME. CNS-directed gene therapy for lysosomal storage
45
46 diseases. Acta Paediatr Suppl. 2008; 97(457):22–27.
47
48
49
50
51 21. Di Domenico C, Villani G, Di Napoli D, et al. Intracranial gene delivery of LV-NAGLU
52
53 vector corrects neuropathology in murine MPS IIIB. Am J Med Genet A. 2009; 149A
54
55

(6):1209–1218.

22. Cearley CN and Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. *J Neurosci*. 2007; 27(37):9928–9940.
23. Lin SP, Lin HY, Wang TJ, et al. A pilot newborn screening program for mucopolysaccharidosis type I in Taiwan. *Orphanet J Rare Dis*. 2013; 8: 147.
24. Scott CR, Elliott S, Buroker N, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. *J Pediatr*. 2013; 163(2):498–503.
25. Ruijter GJ, Goudriaan DA, Boer AM, et al. Newborn screening for hunter disease: a small-scale feasibility study. *JIMD Rep*. 2014; 14: 23–27.
26. Van Diggelen OP, Zhao H, Kleijer WJ, et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A. (MPS IV A). *Clin Chim Acta* 1990;187:131–40.
27. Tylki-Szymanska A, Czartoryska B, Bunge S, et al. Clinical, biochemical and molecular findings in a two-generation Morquio A family. *Clin Genet* 1998;53:369–74.

28. Camelier MV, Burin MG, De Mari J, Vieira TA, Marasca G, Giugliani R. Practical and reliable enzyme test for the detection of mucopolysaccharidosis IVA (Morquio Syndrome type A) in dried blood samples. Clin Chim Acta. 2011 Sep 18;412(19-20):1805-8.

29. Kumar AB, Masi S, Ghomashchi F, et al. Tandem Mass Spectrometry Has a Larger Analytical Range than Fluorescence Assays of Lysosomal Enzymes: Application to Newborn Screening and Diagnosis of Mucopolysaccharidoses Types II, IVA, and VI. Clin Chem. 2015; 61: 1363-71.

30. Duffey TA, Khaliq T, Scott CR, et al. Design and synthesis of substrates for newborn screening of Maroteaux-Lamy and Morquio A syndromes. Bioorg Med Chem Lett. 2010; 20: 5994–5996.

31. Khaliq T, Sadilek M, Scott CR, et al. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis IVA. Clin Chem. 2011; 57: 128–131.

32. National Committee for Clinical Laboratory Standards (NCCLS). Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard-Fourth Edition, NCCLS document LA4-A4. 2003. 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, National Committee for Laboratory Standards.

33. De Jesus V, Zhang XK, Keutzer J, et al. Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage

- disorders. Clin Chem. 2009; 55(1):158–164.
34. Meikle PJ, Grasby DJ, Dean CJ, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab. 2006; 88(4):307–314.
35. Parkinson-Lawrence EJ, Muller VJ, Hopwood JJ, et al. N-acetylgalactosamine-6-sulfatase protein detection in MPS IVA patient and unaffected control samples. Clin Chim Acta. 2007; 377(1-2):88–91.
36. Sukegawa K, Nakamura H, Kato Z, et al. Biochemical and structural analysis of missense mutations in N-acetylgalactosamine-6-sulfate sulfatase causing mucopolysaccharidosis IVA phenotypes. Hum Mol Genet. 2000 May 22;9(9):1283-90.
37. Montañó AM, Sukegawa K, Kato Z, et al. Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase. J Inherit Metab Dis. 2007 Oct;30(5):758-67.
38. Tomatsu S, Montañó AM, Nishioka T, et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum Mutat. 2005 Dec;26(6):500-12.

39. Tomatsu S, Gutierrez M, Nishioka T, et al. Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase. Hum Mol Genet. 2005 Nov 15;14(22):3321-35.

40. Tomatsu S, Fujii T, Fukushi M, et al. Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab. 2013; 110(1-2):42–53.

41. Tomatsu S, Kubaski F, Sawamoto K, et al. Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry. Nihon Masu Sukuriningu Gakkai Shi. 2014; 24: 19–37.

42. Tomatsu S, Shimada T, Mason RW, et al T. Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. J Anal Bioanal Tech. 2014 Mar 1; 2014(Suppl 2): 006

43. Tan MA, Dean CJ, Hopwood JJ, et al. Diagnosis of metachromatic leukodystrophy by immune quantification of arylsulphatase A protein and activity in dried blood spots. Clin Chem. 2008; 54(11):1925-7.

44. Fuller M, Tucker JN, Lang DL, et al. Screening patients referred to a metabolic clinic for lysosomal storage disorders. J Med Genet. 2011; 48(6):422-5.

45. Parkinson-Lawrence E, Fuller M, Hopwood JJ, et al. Immunochemistry of lysosomal storage disorders. Clin Chem. 2006; 52(9):1660-8.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
46. Fuller M, Brooks DA, Evangelista M, et al. Prediction of neuropathology in mucopolysaccharidosis I patients. *Mol Genet Metab.* 2005; 84(1):18-24.
47. Bond CS, Clements PR, Ashby SJ, et al. Structure of a human lysosomal sulfatase. *Structure.* 1997; 5: 277-89.
48. Lukatela G, Krauss N, Theis K, et al. Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. *Biochemistry.* 1998; 37: 3654-64.
49. Rivera-Colón Y, Schutsky EK, Kita AZ, Garman SC. The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A. *J Mol Biol.* 2012; 423(5):736-51.

Figure legends



Figure 1. Schematic representation of the Bio-Plex immunoassay. The anti-GALNS antibody-coated magnetic beads (capture beads) reacts and binds with GALNS protein from the DBS sample then reacts with biotininated detection antibodies.

Figure 2. The specificities of capture (primary) and detection (secondary) antibodies to antigen (GALNS) have been assured by employing dot-blotting assays (A) and western blotting (B). Both results showed good specificity of this method. Either capture (SAB 1410481; 1:1000) or detection antibody (abcam 69957; 1:1000) showed high specificity to the GALNS antigen. By treating with anti-GALNS antibody, the 58 kDa precursor and 40 kDa mature polypeptides were observed in the wild-type human white blood cell homogenates. The loading control of molecular weight markers are indicated on the left.

Figure 3. The GALNS concentrations (ranges) in dried blood spots from normal control ($17.86 \pm 4.78 \mu\text{g/L}$, $n=356$), carriers ($14.17 \pm 1.52 \mu\text{g/L}$, $n=3$) and confirmed MPS IVA patients ($0.88 \pm 0.19 \mu\text{g/L}$, $n=11$).

Figure 4. Sampling to determine the reference values of GALNS in newborn controls showed normal distribution (5,000 samples, Shapiro-Wilk Test, $p=0.354$).


Figure 5. A diagnostic algorithm for MPS IVA newborn screening test.

Figure 2.**(A)****(B)**

The specificities of capture (primary) and detection (secondary) antibodies to antigen (GALNS) have been assured by employing dot-blotting assays (A) and western blotting (B). Both results showed good specificity of this method. Either capture (SAB 1410481; 1:1000) or detection antibody (abcam 69957; 1:1000) showed high specificity to the GALNS antigen. By treating with anti-GALNS antibody, the 58 kDa precursor and 40 kDa mature polypeptides were observed in the wild-type human white blood cell homogenates. The loading control of molecular weight markers are indicated on the left.


134x180mm (300 x 300 DPI)

Figure 1.



Schematic representation of the Bio-Plex immunoassay. The anti-GALNS antibody-coated magnetic beads (capture beads) reacts and binds with GALNS protein from the DBS sample then reacts with biotinated detection antibodies.


148x80mm (300 x 300 DPI)

Figure 3.

The GALNS concentrations (ranges) in dried blood spots from normal control ($17.86 \pm 4.78 \mu\text{g/L}$, $n=356$), carriers ($14.17 \pm 1.52 \mu\text{g/L}$, $n=3$) and confirmed MPS IVA patients ($0.88 \pm 0.19 \mu\text{g/L}$, $n=11$).

96x82mm (300 x 300 DPI)

Figure 4.




Sampling to determine the reference values of GALNS in newborn controls showed normal distribution (5,000 samples, Shapiro-Wilk Test, $p=0.354$).

108x71mm (300 x 300 DPI)

Figure 5.

Proposed algorithm for MPS IVA newborn screening



A diagnostic algorithm for MPS IVA newborn screening test.

170x199mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract Page # 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page # 3, 4
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page # 6,7, 8
Objectives	3	State specific objectives, including any prespecified hypotheses Page # 6,7, 8
Methods		
Study design	4	Present key elements of study design early in the paper Page # 8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page # 9, 10
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants Page # 9
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page # 9-11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page # 10-12
Bias	9	Describe any efforts to address potential sources of bias Page # 9-12
Study size	10	Explain how the study size was arrived at Page # 9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page # 11-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page # 10-13
		(b) Describe any methods used to examine subgroups and interactions Page # 10-11
		(c) Explain how missing data were addressed
		(d) If applicable, describe analytical methods taking account of sampling strategy Page # 11-13
		(e) Describe any sensitivity analyses Page # 10, 13
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page # 14-15
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram Page # 15-16
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page # 14-16
		(b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures Page # 14-16
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Page # 14-16

		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Page # 14-16
Discussion		
Key results	18	Summarise key results with reference to study objectives Page # 17, 18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page # 18, 19
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page # 17-20
Generalisability	21	Discuss the generalisability (external validity) of the study results Page # 17-21
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page # 1, 22

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.